Cover Page  for Protocol  
 
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN6018 -4779  
Official title of study:  A Phase 2, Randomized, Double -Blind, Placebo -Controlled 
Trial to  Evaluate REduction in Inflammation in PatientS with 
advanced  Chronic Renal Disease Utilizing Antibody MEdiated 
IL-6 inhibition  (RESCUE)  
Document date  23 December  2019 
 
 
A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
Amendmen t No. 5
Corvidia Therapeutics Inc.   
Page 1 of 142 A Phase 2, Randomized, Double-B
lind,  Placebo-Controlled Trial to 
Evaluate REduction in Inflammation in PatientS with advanced 
Chronic Renal Disease Utilizing Anti body MEdiated IL-6 inhibition 
(RESCUE) 
DRUG NAME: [CONTACT_244162] (human monoclonal antibody to IL-6) 
PROTOCOL 
NUMBER:  COR-001-02 
PHASE: 2 
IND: 140,097 
TRIAL SPONSOR: Corvidia Therapeutics Inc. 
[ADDRESS_296797]  
Waltham MA [ZIP_CODE]  
MEDICAL 
MONITOR:   
 
Corvidia Therapeutics  Inc. 
Phone:  
Email:  
DOCUMENT DATES: Original: 05 November 2018 
Protocol Amendment 1: 05 December 2018 
Protocol Amendment 2: 24 January 2019 
Protocol Amendment 3: 16 April 2019 
Protocol Amendment 4: 25 June 2019 
Protocol Amendment 5: 23 December 2019 
Confidentiality Statement   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
1 of 142
Redacted protocol  
Includes redaction of personal identifiable information only.  
. 

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 2 of 142 INVESTIGATOR‚ÄôS AGREEMENT  
I have read the attached protocol entitled ‚Äú A Phase 2, Randomized, Double-Blind, 
Placebo-Controlled Trial to Evaluate REduction in Inflam mation in PatientS with 
advanced Chronic Renal Disease Utilizin g Antibody MEdiated IL-6 inhibition 
(RESCUE)‚Äù and  agree to abide by [CONTACT_3769]. 
I agree to comply with the International Council for Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice (GCP) and applicable Food and Drug Administration 
(FDA) regulations/guidelines set forth in [ADDRESS_296798] of the clinical investigation without the prior written consent of Corvidia Therapeutics Inc. 
 
 
   
Signature [CONTACT_789]  
 
 
   
[CONTACT_121365] (Print)   Date (DD Month YYYY)  
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
2 of 142

$3KDVH7ULDOWR(YDOXDWH5(GXFWLRQLQ,QIOD[COMPANY_003]WLRQLQ3DWLHQ W6ZLWKDGYDQFHG 3URWRFRO&25
&KURQLF5HQDO'LVHDVH8WLOL]LQJ$QWLERG\0(GLDWHG,/LQKLELWL RQ 5(6&8( 'HFHPEHU
$PHQGPHQW1R
&RUYLGLD7KHUDSHXWLFV,QF 
3DJHRISPONSOR APPROV AL PAGE
3URGXFWQDPH =LOWLYHNLPDE
3URWRFRO7LWOH $3KDVH5DQGRPL]HG 'RXEOH%OLQG 3ODFHER&RQWUROOHG
7ULDOWR(YDOXDWH5(GXFWLRQLQ,QIOD[COMPANY_003]WLRQLQ3DWLHQW6ZLWKDGYDQFHG&KURQLF5HQDO'LVHDVH8WLOL]LQJ$QWLERG\0(GLDWHG,/
LQKLELWLRQ5(6&8(
3URWRFROQXPEHU &25
5HOHDVHGDWH 'HFHPEHU 
:HWKHXQGHUVLJQHGFRQILUPWKDWWKLV&OLQLFDO6WXG\3URWRFRO LVDFFXUDWH
6LJQHG  'DWH
&RUYLGLD7KHUDSHXWLFV,QF
6LJQHG   'DWH 


3URWRFRO$PHQGPHQW&25B3URW$PHQGB9B'HF_
(;
RI
A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 4 of 142 TABLE OF CONTENTS 
INVESTIGATOR‚ÄôS AGREE MENT .........................................................................................[ADDRESS_296799] OF ABBREVIATIONS, DEFINITIONS AND TERMS ...............................................22  
1 INTRODUCTION .................................................................................................26  
1.1 Background ......................................................................................................26  
1.1.1  Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with 
CKD .....................................................................................................26  
[IP_ADDRESS]  Study of Heart and Renal Protection (SHARP) ..........................26  
[IP_ADDRESS]  CANTOS (Canakinumab Anti-inflammatory Thrombosis 
Outcome Study) ..........................................................................27  
[IP_ADDRESS]  CANTOS hs-CRP Threshold Analysis .......................................27  
[IP_ADDRESS]  CANTOS Patients with Moderate CKD .....................................28  
[IP_ADDRESS]  Modulation of the interleukin-[ADDRESS_296800] and 
incidence rates of atherosclerotic events and all-cause mortality in CANTOS .................................................................28
 
1.1.2  Congestive Heart Failure, Primarily Heart Failure with Preserved 
Ejection Fraction (HFpEF) ..................................................................29  
1.1.3  Functional Iron Deficiency (the Anemia of Chronic Disease) ............31  
1.1.4  Malnutrition-Inflammation-Cachexia Syndrome including 
hypoalbuminemia .................................................................................32  
1.2 Description of Ziltivekimab .............................................................................33  
1.3 Summary of Relevant Nonclinical Experience with Ziltivekimab ..................34  
1.4 Summary of Relevant Clinical Experience with Ziltivekimab ........................34  
1.4.1  Phase 1 Study in Rheumatoid Arthritis Patients (D4430C00001) .......34  
1.4.2  Phase 1 Study in Patients with CKD (COR-001-SC1) ........................35  
1.4.3  Phase 1/2 Study in CKD Patients on Hemodialysis (COR-001-01) ....36  
1.4.4  Conclusions on Ziltivekimab Treatment of Anemia in CKD ..............38  
2 STUDY GOAL AND OBJECTIVES ....................................................................39  
2.1 Primary objective: ............................................................................................39  
2.2 Secondary objectives: ......................................................................................39  
2.3 Pharmacokinetic objectives: ............................................................................39  
2.4 Safety objectives: .............................................................................................39  
2.5 Exploratory objectives: ....................................................................................39    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
4 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 5 of 142 3 INVESTIGATIONAL PLAN ................................................................................41  
3.1 Overall Study Design and Plan: Description ...................................................41  
3.1.1  Pharmacokinetic and PK-PD Modeling ...............................................41  
3.1.2  Safety Endpoints ..................................................................................42  
3.1.3  Pharmacodynamic Endpoints ...............................................................42  
[IP_ADDRESS]  Primary ........................................................................................42  
[IP_ADDRESS]  Secondary ....................................................................................42  
[IP_ADDRESS]  Exploratory .................................................................................43  
3.2 Study Schematic...............................................................................................46  
3.3 Blinding and Randomization ...........................................................................46  
3.3.1  Randomization .....................................................................................46  
3.3.2  Blinding................................................................................................46  
3.3.3  Unblinding ...........................................................................................46  
3.4 Duration of the Study ......................................................................................47  
3.5 Discussion of Study Design, Including Choice of Control Arm .....................47  
3.5.1  Study Population and Control Arm......................................................47  
3.5.2  Rationale for Dosing and Length of Safety Evaluation .......................47  
3.5.3  Rationale for the Efficacy Endpoints ...................................................48  
3.5.4  Rationale for the Dose Regimens ........................................................49  
[IP_ADDRESS]  Pharmacokinetic modeling..........................................................50  
[IP_ADDRESS]  Correspondence of proposed doses to those used in prior 
clinical studies.............................................................................50  
[IP_ADDRESS]  Exposure for proposed doses relative to IL-6 binding ................51  
[IP_ADDRESS]  Exposures for proposed doses relative to the exposures at 
NOAEL dose in the toxicology study .........................................51  
[IP_ADDRESS]  Exposures for proposed doses relative to the exposures 
associated with clinically meaningful PD changes in prior 
clinical studies.............................................................................51  
3.6 Safety Plan and Monitoring .............................................................................52  
3.7 Benefit and Risk Assessment ...........................................................................52  
4 SELECTION OF STUDY POPULATION AND CRITERIA FOR WITHDRAWAL....................................................................................................53
 
4.1 Inclusion Criteria .............................................................................................53  
4.2 Exclusion Criteria ............................................................................................53  
4.3 Criteria for Discontinuation of Study Drug .....................................................56  
4.4 Anaphylaxis Study Stoppi[INVESTIGATOR_10020] ...................................................................56  
4.5 Temporary Discontinuation of Study Intervention ..........................................57  
4.6 Participant Discontinuation/Withdrawal from the Study .................................[ADDRESS_296801]-to-Follow-up ............................................................................................58  
4.8 Study Completion ............................................................................................58    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
5 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 6 of 142 5 ENROLLMENT AND STUDY PROCEDURES .................................................59  
5.1 Screening Visit Procedures (Up to 2 weeks, Days -14 to -7) ‚Äì Initial 
Screening..........................................................................................................63  
5.2 Screening Visit Procedures (Week -1; Days -7 to -1) ‚Äì Full Screening ..........63  
5.3 Treatment Period (Study Weeks 1 - 21) ..........................................................64  
5.3.1  Visit 1, Week 1, Day 1 (Pre-Dose) ......................................................64  
5.3.2  Visit 1, Week 1, Day 1 (Dosing/Post-Dose) ........................................65  
5.3.3  Visit 2, Week 2, Day 8 .........................................................................66  
5.3.4  Visit 3, Week 4, Day 22 .......................................................................66  
5.3.5  Visit 4, Week 5 ....................................................................................66  
5.3.6  Visit 5, Week 7 ....................................................................................67  
5.3.7  Visits 6 through 9, Weeks 9 through 21 ..............................................67  
5.3.8  Visits 6 through 9, Weeks 9 through Week 21 (Dosing/Post-Dose) ...69  
5.3.9  Visit 10, Week 23 and Visit 11, Week 24/ET......................................69  
5.4 Safety Follow-Up Visits 12 and 13 Procedures (Study Weeks 28 and 32) .....[ADDRESS_296802]..............................................................................................................81  
9.8 Pregnancy Reporting ........................................................................................82    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
6 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 7 of 142 10 STUDY ASSESSMENTS .....................................................................................83  
10.1  Pharmacodynamic Assessments ......................................................................83  
10.1.1  CKD symptoms, Fatigue, and Health-Related Quality of Life ............83  
10.1.2  Laboratory Assessments ......................................................................83  
10.2  Safety Assessments (other than Adverse Events) ............................................83  
10.2.1  Vital Signs ............................................................................................83  
10.2.2  12-lead ECG.........................................................................................83  
10.2.3  Physical Examination...........................................................................84  
10.2.4  Clinical Laboratory Testing .................................................................84  
11 STATISTICAL CONSIDERATIONS AND DATA ANALYSIS ........................85  
11.1  Sample Size ......................................................................................................85  
11.2  Randomization .................................................................................................85  
11.3  General Statistical Considerat ions and Definitions .........................................85  
11.3.1  General Statistical Methods .................................................................85  
11.3.2  Analysis Populations ............................................................................85  
11.3.3  Analysis Windows and Baseline ..........................................................86  
11.3.4  Missing Data Handling ........................................................................86  
11.4  Statistical Analyses ..........................................................................................86  
11.4.1  Demographic and Background Characteristics ....................................86  
11.4.2  Study Drug and Concomitant Medications ..........................................86  
11.4.3  Efficacy Analysis .................................................................................87  
11.4.4  Efficacy Variables ................................................................................87  
[IP_ADDRESS]  Primary ........................................................................................88  
[IP_ADDRESS]  Secondary ....................................................................................88  
[IP_ADDRESS]  Exploratory .................................................................................88  
[IP_ADDRESS]  Multiple Comparisons Procedure for Primary Efficacy and 
Secondary Endpoints ..................................................................93  
11.4.5  Safety Analysis ....................................................................................93  
[IP_ADDRESS]  Adverse Events ...........................................................................93  
[IP_ADDRESS]  Laboratory Tests .........................................................................94  
[IP_ADDRESS]  Vital Signs ...................................................................................94  
[IP_ADDRESS]  12-lead ECG................................................................................95  
[IP_ADDRESS]  Physical Examination..................................................................96  
[IP_ADDRESS]  Antibodies to Ziltivekimab .........................................................96  
[IP_ADDRESS]  Bleeding Events ..........................................................................96  
11.4.6  Pharmacokinetic Analysis and Ph armacokinetic/Pharmacodynamic 
Analysis................................................................................................96  
[IP_ADDRESS]  Pharmacokinetic Data .................................................................96  
[IP_ADDRESS]  Pharmacokinetic/Pharmacodynamic Analysis ............................97    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
7 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 8 of 142 11.4.7  Exploratory Analyses of Efficacy and Safety Endpoints Based on 
Base line Hemoglobin ( ‚â•11 or <11 g/dL).  ............................................97  
11.5  Interim Analyses ..............................................................................................97  
12 STUDY COMMITTEES .......................................................................................98  
12.1  Clinical Events Committee ..............................................................................98  
12.2  Safety Assessment Committee (SAC) .............................................................[ADDRESS_296803] or Independent Ethics Committee .......................99  
13.2  Informed Consent.............................................................................................99  
13.3  Supplementary Documentation ........................................................................99  
13.4  Data Reporting and Case Report Forms ........................................................100  
13.5  Retention of Data ...........................................................................................100  
13.6  Deviation from the Protocol...........................................................................100  
13.7  Study Monitoring ...........................................................................................101  
13.8  Drug Accountability.......................................................................................101  
13.9  Disclosure of Data..........................................................................................101  
14 REFERENCES ....................................................................................................102  
15 APPENDICES .....................................................................................................109  
15.1  Appendix A Exclusionary Drugs ...................................................................109  
15.2  Appendix B PROMIS¬Æ (Patient-Reported Outcomes Measurement 
Information System) ......................................................................................110  
15.3  Appendix C Optum SF-36 v2¬Æ Health Survey .............................................112  
15.4  Appendix D Corvidia ePRO ..........................................................................116  
15.5  Appendix E PGIS and PGIC ..........................................................................137  
15.6  Appendix F EurQol-5D-5L (EQ-5D-5L) .......................................................139  
15.7  Appendix G Guidance on Contraception .......................................................141  
     Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
8 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296804] OF TABLES 
Table 1  Summary of IV doses used in Study COR-001-01 with SC doses that 
represent corresponding exposure..............................................................51  
Table 2  SCHEDULE OF PROCEDURES..............................................................60  
Table 3  Planned Ziltivekimab Doses and Administered Volumes .........................73  
Table 4  Composition for Ziltivekimab for Injection, Amount per mL (7.5 mg/Vial, 15 mg/Vial, 30 mg/Vial, and Placebo) .......................................73
 
Table 5  Severity Assessment for AEs and Abnormal Laboratory Values ..............80  
Table 6  Pre-defined Threshold Va lue for Vital Signs .............................................95  
Table 7  Pre-defined Threshold Value for ECG ......................................................95  
Table 8  TIMI Bleeding Classification ....................................................................96  
 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
9 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296805] OF FIGURES 
Figure 1  A conceptual framework of contributors to the cardiovascular disease 
burden in patients with advancing CKD ....................................................30  
Figure 2  A model for the influence of genetic variation on IL-6 ‚Äìmediated 
cellular iron handling .................................................................................34  
Figure 3  Percentage of CKD patients treated with Ziltivekimab or Placebo who achieved an hs-CRP level of < 2.0 mg/L from Baseline to Week [ADDRESS_296806] Patients .........................................................................37
 
Figure 5  Study Flow .................................................................................................46  
 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
10 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 11 of 142 PROTOCOL SYNOPSIS 
Title A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to 
Evaluate REduction in Inflammation in PatientS with advanced 
Chronic Renal Disease Utilizing Antibody MEdiated IL6 
Inhibition  (RESCUE) 
Study Number COR-001-02 
Study Phase 2 
Objectives Patients with non-dialysis-dependent chronic kidney disease (NDD-
CKD) , who have evidence of systemic inflammation with increased 
cardiovascular  risk, will be enrolled into this trial . The purpose of 
this trial is to determine a dose to select for a potential 
cardiovascular outcome trial with Ziltivek imab. 
Primary objective:  
x To evaluate the effects of Ziltivekimab compared to placebo on 
markers of inflammation (i.e. high-sensitivity C- reactive protein 
[hs-CRP]). 
Secondary objectives: 
x To evaluate the effects of Ziltivekimab compared to placebo on 
markers of inflammation and cardiovascular risk: serum 
amyloid A (SAA) and fibrinogen. 
Pharmacokinetic objectives:  
x To evaluate the pharmacokinetics (PK) and PK-Pharmacodynamic (PK-
PD) modeling of Ziltivekimab following 
multiple doses at three different levels. 
Safety objectives: 
x To evaluate the safety of three dose levels of Ziltivekimab compared to placebo. 
Exploratory objectives:   
x To evaluate the effects of Ziltivekimab compared to placebo on 
markers of anemia (hemoglobin). 
x To evaluate the effects of Ziltivekimab compared to placebo on 
markers of inflammation-malnutrition (i.e. albumin). 
x To evaluate the effects of Ziltivekimab compared to placebo on 
markers of cardiovascular risk (i.e. N-terminal prohormone- B-
type natriuretic peptide [NT-pro-BNP]). 
x To evaluate the effects of Ziltivekimab compared to placebo on 
additional markers of cardiovascular risk (suppression of tumorigenicity 2 [ST2]). 
x To evaluate the effects of Ziltivekimab compared to placebo on   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
11 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 12 of 142 markers of atherosclerosis risk: LDL-C, triglycerides, ApoB, 
ApoA1, ApoB/ApoA1, lipid profile by [CONTACT_244096] (NMR) spectroscopy, and Lp(a).  
x To evaluate the effects of Ziltivekimab compared to placebo on 
markers of kidney function, (i.e. cystatin C, estimated GFR) and 
kidney damage, (i.e. urine albumin-to-creatinine ratio [UACR ]). 
x To evaluate the effects of three dose levels of Ziltivekimab 
compared to placebo on patient reported outcomes (PRO): Patient-
Reported Outcomes Measurement Information System 
(PROMIS¬Æ) Fatigue 13a short form, selected items from the 
PROMIS fatigue item bank, the Optum SF-36 v2¬Æ Health 
Survey, a Corvidia PRO, the P ROMIS interest in sexual activity 
item, the patient global impression of change (PGIC), patient 
global impression of severity (PGIS), and the EQ-5D-5L.  
x To evaluate the psychometric properties of the PROMIS Fatigue 
13a short form and selected items from the PROMIS fatigue item 
bank, and the Corvidia electronic PRO (ePRO) items in CKD 
patients. 
x To evaluate the effects of Ziltivekimab on systemic iron 
availability:  transferrin saturation (TSAT), reticulocyte hemoglobin content (CHr) and total iron binding capacity 
(TIBC), systemic iron stores (serum ferritin), serum iron and systemic iron regulation (serum hepcidin). 
x
 To evaluate the effects of Ziltivekimab compared to p lacebo on 
markers of cardiovascular risk (i.e. NT-pro-BNP) in patients with 
baseline NT-pro-BNP > 250 pg/mL. 
x To evaluate the effects of Ziltivekimab compared to placebo on 
markers of anemia in patients with baseline hemoglobin < 11 
g/dL.  
x To evaluate the e ffects of Ziltivekimab compared to placebo on 
markers of inflammation- malnutrition (i.e. albumin) in patients 
with baseline albumin < 4.0 g/dL. 
Study Design This is a randomized, double-blind, placebo-controlled trial designed 
to evaluate the efficacy, safety, and pharmacokinetics of Ziltivekimab 
at three dose levels (7.5 mg, 15 mg or 30 mg) compared to placeb o in 
patients with stage [ADDRESS_296807] evidence of 
inflammation  with high cardiovascular risk.  
Patients  will undergo a Screening Period of up to 14-days during 
which inclusion and exclusion criteria will be evaluated. Patients 
who meet all inclusion criteria a nd no exclusion criteria will be 
randomized to one of t hree Ziltivekimab dose levels (7.5 mg, 15 mg 
or 30 mg)  or placebo for a 24-week Treatment Period. Patient 
randomization  will be stratified by [CONTACT_244097] ( ‚â•11 or < 11 
g/dL ) and CKD stage (3, 4 or 5).    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
12 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 13 of 142 Approximately 240 patients will be ra ndomized 1:1:1:1 (60 per 
group) into the trial. All patients must meet the incl usion/exclusion 
criteria. After the Screening Period, randomized patients will be 
dosed every 28 days out to Week 21 . The primary, secondary and 
exploratory endpoints will be analyzed after 13 weeks of treatment 
and then followed for additional exploratory efficacy analyses 
through Week 24. Selected efficacy endpoints and safety 
assessment s will evaluated in the Follow-up Period Week 25 though 
Week 3 2 (Figure 5 ). 
The patient will be randomized on Day [ADDRESS_296808]  dose of study 
drug should be administered after all assessments are conducted.  
Doses of study drug will be administered every 28- days for a total of 
6 treatments  (Weeks 1, 5, 9, 13, 17, and 21) . Study visits will follow 
the schedule of events ( Table 2 ). 
Study Periods: The study will consist of three periods:  Screening, Treatment 
Period, and Safety Follow -Up Period. The total study duration fo r an 
individual patient will be approximately 8-9 months. 
Screening Perio d: up to 2 weeks [Days -14 to -1]  
x Starts with the first date th at Initial Screening procedures 
were performed. The first procedure also defines the initial 
screening visit date 
Treatment Period: 24 weeks [Week 1, Day [ADDRESS_296809] administration of study 
drug/randomization (Day 1) 
Safety Follow-Up Period: 8 weeks [Weeks 25 through 32] 
x Safety period starts 4-weeks after last treatment dose 6. 
Inclusion Criteria: After signing an informed consent form approved by [CONTACT_3786]‚Äôs  Institutional Review Board (IRB) or Independent 
Ethics Committee (IC) t o be eligible, potential study patients mus t 
meet all of the following criteria: 
1) Age ‚â•18 years at the time of signing of the Informed Consent 
Form (ICF).   
2) Stage 3-5 NDD-CKD, i.e. esti mated glomerular filtration rate 
(eGFR) >10 and <60 mL/min/1.73 m2 using the CKD-EPI 
[INVESTIGATOR_91258] ( www.kidney.org/content/ckd-epi- creatinine-
equation-2009).  
3) Serum hs-CRP level t2.0 mg/L measured durin g the Screening 
Period. (Note: Targeting patients with a history of advanced stage 
CKD, atherosclerotic cardiovascular disease , anemia, metabolic 
syndrome, diabetic retinopathy  and diabetes for screening will help 
increase the chances of identifying patients with CRP ‚â•2.0) 
4) The patient agrees to comply with the contraception and 
reproduction restrictions of the study ( Appendix G ):   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
13 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 14 of 142 a) Women of childbearing potential must be using a method of 
contraception, that is ‚Äúhighly effective‚Äù (i.e., <1% failure 
rate) for at least [ADDRESS_296810] dose of study 
drug; 
b) Postmenopausal women must have had no menstrual blee ding 
for at least [ADDRESS_296811] an elevated plasma follicle-
stimulating hormone (FSH) level (i.e., >40 mIU/mL) at Screening; 
c) Women of childbearing potential must have a documented
 
negative pregnancy test result at Screening . Patients with 
elevated Œ≤-HCG levels believed to be due to end- stage renal 
disease may be enrolled if documented to not be pregnant; 
AND 
d) All m ale patients, from the day of dosing until the final study 
visit, unless surgically sterile, must be willing to use a 
condom with a partner (male patients with partners of 
childbearing potential must be willing to use 2 effective methods of birth control, 1 should be condom with 
spermicide) to prevent pregnancy and drug exposure of a 
partner, and refrain from donating sperm or fathering a ch
ild. 
Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
 
Laboratory Values  
1. Absolute neutrophil count <2.0 x 109/L during screening. 
2. Platelet count <120 x 109/L during screening. 
3. Spot urine protein to creatinine ratio >4000 mg/g, or 4.0 
g/g. 
4. Alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) >2.5x ULN during screening. 
5. Positive testing for tuberculosis (TB) during screening. 
Blood testing (e.g., QuantiFERON) is preferred but a 
purified protein derivative ([COMPANY_003]) skin test read within 
48-72 hours by a qualified healthcare professional may 
also be performed. If a patient is [COMPANY_003] positive but 
QuantiFERON negative the patient is eligible.  
6. Evidence of human immunodeficiency virus-1 (HIV- 1) 
or HIV-2 infection by [CONTACT_244098]. 
7. Hepatitis B or C by [CONTACT_44898] (e.g. hepatitis B surface antigen or hepatitis C antib ody positive) measured during 
screening.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
14 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296812]-randomization. 
9. Thromboembolic event within 12-weeks prior to 
randomization. 
10. Clinical evidence or suspi[INVESTIGATOR_244065]. 
11. History of peptic ulcer disease or gastrointestinal 
ulceration in the 12-months prior to randomization. 
12. History of active diverticulitis in the 12- months prior to 
randomization. 
13. History of inflammatory bowel disease that has been 
clinically active during the 12-months prior to 
randomization. 
14. Uncontrolled hypertension (defined as an average SBP 
>160 mmHg or an average diastolic blood pressure 
(DBP) >100 mmHg during screening.  Patients may be 
re-evaluated within 2 weeks, at the discretion of the investigator for this criterion if anti-
hypertensive therapy 
has been started or increased as a result of initial 
screening blood pressure being above these limits. 
15. Planned coronary revascularization (PCI or CABG) or 
any other major surgical procedure. 
16. Major cardiac surgical, non- cardiac surgical or major 
endoscopic procedure within the past 6 months prior to 
Randomization. 
17. History of [LOCATION_001] Heart Association Class IV congestive heart failure within 12-weeks prior to 
randomization. 
18. Actively treated or active malignancy during the 1-
year 
prior to randomization with the exception of successfully 
treated nonmetastatic basal cell or squamous cell 
carcinomas of the skin and/or local carcinoma in situ of 
the cervix. 
19. History of bone marrow or solid organ transplant or 
anticipated to receive an organ transplant during the time 
frame of the study. 
20. Known allergy to the study drug or any of its ingr edients. 
Prior or Current Medications  
21. Received an investigational drug within 30- days prior to 
screening visit. 
22. Received a live vaccine product within 14 days of study 
drug administration (Day 1) or expect to receive live   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
15 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 16 of 142 vaccine during the Treatment Period (receiving a live 
vaccine within 14 days prior to enrollment is allowed). 
23. Treatment with a hypoxia-inducible factor (HIF) 
stabilizer (e.g., molidustat, roxadustat) or an 
erythropoietin-mimetic, e.g., erythropoietin alpha or 
beta, darbopoietin alpha, or c ontinuous erythropoiesis 
receptor activator (CERA), within 6-weeks prior to 
randomization or during treatment period. 
24. Expected to receive any investigational drug or any of the 
exclusionary drugs listed in Section 15.1 during the 
Treatment Period or Safety Follow-Up Period. 
25. Chronic use of systemic immunosuppressive drugs 
during the screening period or anticipated use of such 
drugs any time during the study. Note: Use of otic, 
ophthalmic, inhaled, and topi[INVESTIGATOR_244066]. Oral 
prednisone up to 5 mg per day is (or equivalent) is 
permitted if dose has been stable for at least 4 weeks prior to screening, and no dose changes are planned 
during study participation. 
26. Use of systemic antibiotics, systemic antivirals, or systemic antifungals during the screening period 
(‚ÄúSystemic‚Äù is defined as oral or intravenous drugs that 
are absorbed into the circulation). 
27. Requiring an indwelling catheter of any type. 
General Exclusion s 
28. Currently breastfeeding. 
29. Any conditi on that could interfere with, or for which the 
treatment might interfere with, the conduct of the study 
or interpretation of the study results, or that would in the 
opi[INVESTIGATOR_244067]. 
Test Product, Dose and 
Mode of 
Administration  The test product dose regimens to be examined in this study are:  
x Dose #1: Ziltivekimab, 7. 5 mg per injection, administered 6 times 
(every 28-days) on Weeks 1, 5, 9, 13, 17, and 21, as a 
subcutaneous injection. 
x Dose #2: Ziltivekimab, 15 mg per injection, administered 6 times 
(every 28-days) on Weeks 1, 5, 9, 13, 17, and 21, as a subcutaneous injection. 
x
 Dose #3: Ziltivekimab , 30 mg per injection, administered 6 times 
(every 28-days) on Weeks 1, 5, 9, 13, 17, and 21, as a 
subcutaneous injection. 
Patients should receive 6 injections of their assigned dose during the   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
16 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 17 of 142 trial.  The total cumulative dosage will be 45 mg for those patients 
randomized to 7.5 mg per injection,  90 mg for those patients 
randomized to 15 mg per injection, and 180 mg for those patients 
randomized to 30 mg per injection . 
Reference Therapy, 
Dose, and Mode of 
Administration  The reference dose regimens to be examined in this study are: 
x Matched placebo injections administered subcutaneously 6 times 
(every 28 days) at the same frequency as the active treatment in  a 
given dose cohort, on Weeks 1, 5, 9, 13, 17 and 21. 
Pharmacokinetics and 
PK-PD Modeling: x Serum trough levels (C min) of Ziltivekimab will be measured at all 
visits. On dosing Weeks 1, 5, 9, 13, 17, and 21, trough PK 
samples to be collected within approximately -0.5 h pre-dose. 
Single PK blood samples will also be collected on Weeks 2, 4, 7, 
23, 24/ET, 28, and 32/ET around the same time as the pre- dose 
samples were collected on previous dosing visits. 
x The total IL-6 AUC will be described.  
x The relationship between trough Ziltivekimab levels and primary 
pharmacodynamic endpoints, specifically total plasma IL- 6 and 
hs-CRP, will be described.  
Safety Endpoints: 
 x Proportion of patients with AEs, SAEs, severe hematologic AEs, 
severe non- hematologic AEs, and AEs leading to discontinuation. 
x Proportion of subjects with thrombolysis in myocardial infarction 
(TIMI) major bleeding event. 
x Description and frequency of events of special interest by 
[CONTACT_1570]: 
o Serious infections. 
o Severe injection-related reactions. 
o Gastrointestinal perforations. 
o Hypersensitivity reaction during study drug administration.  
o Anaphylaxis occurring at any time, even if considered 
unrelated to the study drug. A CRF for the collection of the 
details of such reactions will be available in the electronic 
data capture (EDC) system. 
o Neutrophil <500/mm3 (severe), or neutrophil <1000/mm3 
(severe ) with evidence of concurrent infection. These events 
will be separately summarized by [CONTACT_21747] d dose. 
o Thrombocytopenia (platelet count <50,000/mm3 [severe ]) or 
platelet count <75,000/mm3 (moderate ) with evidence of 
concurrent TIMI major bleeding. These events will be 
separately summarized by [CONTACT_244099]. 
o Malignancies. 
x Description of additional safety assessments by [CONTACT_244100]-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
17 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 18 of 142 and dose: vital signs, electrocardiogram (ECG), clinical 
laboratory, and anti- drug antibodies (binding and neutralizing). 
Primary Endpoint: x Difference in percent change in hs-CRP levels from Baseline 
(average of the hs- CRP value prior to randomization and Day 1) 
to Week 13 between each active group and placebo. 
Secondary Endpoints: 
 x Difference in change in SAA from Baseline to Week 13 between 
each active group and placebo. 
x Difference in percent change in fibrinogen from Baseline to 
Week 13 between each active group and placebo. 
Exploratory 
Endpoints:  
 x Difference in change in SAA from Baseline to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in percent change in fibrinogen from Baseline to End 
of Treatment (Week 24) between each active group and placebo. 
x Difference in percent change in hs- CRP levels from Baseline to 
End of Treatment (Weeks 23 through 24) between each active 
group and placebo. 
x Difference in percent change in serum NT-pro-BNP from 
Baseline (average of the NT-pro-BNP value prior to 
randomization and Day 1) to Week 13 and to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in change in hemoglobin from Baseline (averag e of 
the two most recent hemoglobin values prior to randomization 
and Day 1) to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x 
Difference in change in serum albumin from Baseline (average 
of the two most recent serum albumin values prior to 
randomization and Day 1) to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Proportion of patients achieving hs- CRP response at Week 13 
and to End of Treatment (Weeks 23 through 24 ), defined as hs-
CRP <2.0 mg/L in each active group and placebo. 
x Difference in change in ST2 from Baseline to Week 13 and to 
End of Treatment (Week 24) between each active group and 
placebo. 
x Difference in percent change in Lp(a) from Baseline to Week 13 
and to End of Treatment (Weeks 23 through 24) between each 
active group and placebo. 
x Difference in percent change in LDL- C, triglycerides, ApoB, 
ApoA1, ApoB/ApoA1, and lipid profile by [CONTACT_244101] 13 and to End of Treatment (Weeks 23 
through 24) between each active group and placebo. 
x Difference in change of creatinine based eGFR and cystatin C-  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
18 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 19 of 142 based eGFR from Baseline to Week 13 and to the End of 
Treatment (Weeks 23 through 24) between each active group 
and placebo. 
x Difference in ch ange of UACR from Baseline to Week 13 and to 
End of Treatment (Weeks 23 through 24) between each active 
group and placebo. 
x Difference in change of the total fatigue score (PROMIS Fatigue 
13a short form and selected items from the PROMIS Fatigue 
item bank) from Baseline to Week 13 and to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in change of the PROMIS interest in sexual activity 
item from Baseline to Week 13 and to End of Treatment (Week 
24) between each active group and placebo. 
x Difference in change of the Corvidia ePRO items from Baseline 
to Week 12 and to End of Treatment (Weeks 23 through 24)  
between each active group and placebo. 
x Difference in change of the PGIS index from Baseline to Week 
12 and to End of Treatment (Week 24) between each active 
group and placebo. 
x Descriptive analyses of the PGIC index at Weeks 5, 13 and End 
of Treatment (Week 24) in each active group and placebo. 
x Difference in change of the Optum SF- 36 v2¬Æ Health Survey 
physical component summary (PCS), mental component 
summary (MCS) and domain scores from baseline to Week 13 
and to End of Treatment (Weeks 23 through 24) between each 
active group and placebo. 
x Difference in change of the EQ-5D- 5L index from Baseline to 
Week 12 and to End of Treatment (Week 24) between each active group and placebo. 
x 
Evaluation of the psychometric properties of the PROMIS Fatigue 
13a short form and selected items from the PROMIS Fatigue item 
bank and the Corvidia ePRO items in CKD patients ‚Äì to be 
described in a PRO psychometric analysis plan. 
x Descriptive analyses by [CONTACT_244102], genomic 
and transcriptomic analysis. 
x Difference in change in TSAT from Baseline to peak level, Week 
13 an d End of Treatment (Weeks 23 through 24), between each 
active group and placebo. 
x Difference in change in CHr from Baseline to peak level, Week 
13 and to End of Treatment (Week 24) between each active group 
and placebo. 
x Difference in change in TIBC from Baseline to Week 13 and to   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
19 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 20 of 142 End of Treatment (Weeks 23 through 24) between each active 
group and placebo. 
x Difference in change in serum ferritin from Baseline to Week 13 
and to End of Treatment (Weeks 23 through 24) between each 
active group and placebo. 
x Diffe rence in change in serum iron from Baseline to Week 13 and 
to End of Treatment (Weeks 23 through 24) between each active 
group and placebo. 
x Difference in change in serum hepcidin from Baseline to Week 13 
and to End of Treatment (Week 24) between each activ e group 
and placebo. 
x Difference in percent change in serum NT-pro-BNP from 
Baseline to Week 13 and to End of Treatment (Weeks 23 through 
24) between each active group and placebo in patients with 
baseline NT-pro-BNP > 250 pg/mL. 
x Difference in change in hem oglobin from Baseline (average of the 
two most recent hemoglobin values prior to randomization and 
Day 1) to Week 13 and to End of Treatment (Weeks 23 through 
24) between each active group and placebo in patients with 
baseline hemoglobin < 11 g/dL. 
x Differe nce in change in serum albumin from Baseline (average of 
the two most recent serum albumin values prior to randomization 
and Day 1) to Week 13 and to End of Treatment (Weeks 23 
through 24) between each active group and placebo in patients 
with baseline albumin < 4.0 g/dL. 
Sample Size Approximately 240 (60 per group). 
Statistical Methods 
Analysis  The following analysis Populations are defined for the different types 
of data analysis:  
x Intent-to- treat (ITT) analysis population: all patients randomized. 
x Per-protocol (PP) analysis population: all patients randomized 
who completed the study and did not incur a significant protocol 
violation. 
x Pharmacokinetics (PK) analysis population: all patients 
randomized and who received at least one dose of Test or Reference product and who had at least one post-
dose PK blood 
sample. 
x Safety analysis population: all patients randomized and who received at least one dose of Test or Reference product. 
All study -collected data will be summarized by [CONTACT_244103], using descriptive statistics, 
graphs, and/or raw data listings. Descriptive statistics for continuous 
variables will include number of patients (n), mean, standard deviation (SD), median, quartiles (Q1 and Q3), minimum (min) and   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
20 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 21 of 142 maximum (max) values for the observed value and change from 
baseline will be reported. Analysis of categorical variables will 
include frequency and percentage.  
For efficacy variables, the difference between each active group and 
placebo  will be presented. A mixed model for repeated measures 
(MMRM) will be used for this purpose, with  baseline hemoglobin 
(‚â•11 or <11 g/dL), CKD stage (3, 4 or 5), treatment groups, visit and 
treatment group -by-visit interaction as categorical fixed effects, 
baseline value and baseline -by-visit interaction will be included as 
covariates. The least square means for each dose, the least square 
mean differences from placebo along with the associated 95% 
confidence intervals (CIs) and p -values will be presented. If the 
normality assumption is not met, a nonparametric test will be selected 
for efficacy analysis.   
Study Centers Approximately 50-60 study sites 
Sponsor Corvidia Therapeutics Inc.  
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
21 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296813] Aspartate aminotransferase 
AUC Area under the curve 
Œ≤-hCG Œ≤ -Human chorionic gonadotropin hormone 
BMP Bone morphogenic protein 
BMPR Bone morphogenic protein receptor 
BP Blood pressure 
BUN Blood urea nitrogen 
CBC Complete blood count 
CEC Clinical Events Committee (CEC)  
CERA Continuous erythropoiesis receptor activator  
CFR Code of Federal Regulations 
CHF Congestive heart failure 
CHr Reticulocyte hemoglobin content 
CKD Chronic kidney disease 
CKD-EPI [INVESTIGATOR_244068]/min Maximum/minimum observed concentration 
Ziltivekimab Monoclonal antibody to IL-[ADDRESS_296814] research organization 
CV Cardiovascular 
CV Coefficient of variation  
CVD Cardiovascular disease 
ECG Electrocardiogram 
EDC Electronic data capture  
ESA  Erythropoiesis-stimulating agent 
eGFR estimated glomerular filtration rate 
ePRO Electronic Patient-Reported Outcomes 
EQ-5D-5L  (EuroQol-5D-5L 
ERI ESA resistance index (ESA weekly dose/targeted dry weight in 
kg*hemoglobin in g/dL) 
ESRD End stage renal disease   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
22 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296815] ratio  
HRQoL Health-related quality of life 
hs-CRP High sensitivity C-Reactive Protein 
IB Investigator‚Äôs Brochure  
ICF Informed Consent Form 
ICH International Council for Harmonisation 
IEC Independent Ethics Committee 
IL1RL-[ADDRESS_296816] 
ITT Intent-to-Treat 
IV Intravenous 
IWRS Interactive Web-Response System 
kg Kilogram 
KDIGO Kidney Disease: Improving Global Outcomes  
LAV Left atrial volume 
LDL Low density Lipoprotein 
LHD Low Hemoglobin density   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
23 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296817] level 
NT-pro-BNP N-terminal prohormone-B-type natriuretic peptide 
PAP Psychometric analysis plan  
PBO Placebo 
PCS Physical component summary 
PD Pharmacodynamic 
PEW protein-energy wasting  
PGIC Patient Global Impression of Change 
PGIS Patient Global Impression of Severity 
PI [INVESTIGATOR_244069]-Reported Outcomes 
PROMIS Patient-Reported Outcomes Measurement Information System 
PROSAP PRO statistical analysis plan  
PT Prothrombin Time 
PTH Parathyroid Hormone 
RBC Red Blood Cell 
RDW Red cell distribution width 
RR Respi[INVESTIGATOR_244070] A 
SAE Serious adverse event    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
24 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296818] Upper limit of normal 
WBC White blood cells   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
25 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 26 of 142 1 INTRODUCTION 
1.1 Background 
Ziltivekimab (COR-001), formerly MEDI5117, is an extended half-life human IgG1Œ∫  
anti-human interleukin 6 (IL-6) monoclonal antibody designed with three amino acid 
substitutions (‚ÄúYTE‚Äù) in the CH2 region of the Fc domain to decrease clearance  and thereby 
[CONTACT_244104]. Ziltivekimab is being develo ped for the treatment of patients with the 
inflammatory sequalae of advanced chronic kidney disease (CKD). Inflammatory sequelae 
specifically include the following: 
x Atherosclerotic Cardiovasc ular Disease (ASCVD) 
x Congestive Heart Failure, Primarily Heart Failure with Preserved Ejection Fraction 
(HFpEF) 
x Functional Iron Deficiency Anemia 
x Malnutrition-Inflammation-Cachexia Syndrome  
1.1.1 Atherosclerotic Cardiovascular Dise ase (ASCVD) in Patients with CKD 
Patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) are 10 times more 
likely to die of atherosclerotic cardiovascu lar disease (ASCVD) than the general population 
(Gregg 2018 ). However, cardiovascular disease is frequently underdiagnosed and 
undertreated in patients with CKD. Inflamma tion is highly prevalent in patients with 
chronic kidney disease (CKD) and is consistently  associated with cardiovascular morbidity 
and mortality. Markers of inflammation, including plasma C-reactive protein (CRP), are 
associated with an increased ri sk of cardiovascular disease, and it has been suggested that 
this association is causal. An abundance of bi ologic, epi[INVESTIGATOR_50123], and clinical trial data 
have demonstrated that inflammation is a key driver of atherosclerosis ( Aday 2019 ). 
Circulating biomarkers of inflammation, includi ng high-sensitivity C-reactive protein (hs-
CRP) and interleukin-6 (IL-6), are associated with  increased risk of cardiovascular events 
independent of cholesterol and other tradition al risk factors. Randomized trials have shown 
that statins reduce hs-CRP, and the magnitude of hs-CRP reduction is proportional to the 
reduction in cardiovascular risk ( Aday 2019 ; Ridker 2018a; Arici 2001 ). 
[IP_ADDRESS] Study of Heart and Renal Protection (SHARP)  
The Study of Heart and Renal Protection (S HARP) assessed the associations between 
circulating CRP and LDL cholesterol levels a nd the risk of vascular and non-vascular 
outcomes ( Storey 2018 ).  Higher baseline CRP was associated with an increased risk of 
major vascular events (hazard ratio per 3x increase 1.28; 95% confidence interval 1.19-1.38). 
Higher baseline LDL cholesterol was also associated with an increased risk of major vascular   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
26 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 27 of 142 events (hazard ratio per 0.6 mmol/L higher LDL cholesterol; 1.14, 1.06-1.22). Higher 
baseline CRP was associated w ith an increased risk of a ra nge of non-vascular events (1.16, 
1.12-1.21), but there was a weak inverse associ ation between baseline LDL cholesterol and 
non-vascular events (0.96, 0.92-0.99). The efficacy of lowering LDL cholesterol with simvastatin/ezetimibe on major vascular events, in the randomized comparison, was similar irrespective of CRP concentrati on at baseline however risk of increased CV events were 
significantly greater in patients who had elevated CRP on treatment. This "residual 
inflammatory risk" has increasingly become a viable pharmacologic target. 
[IP_ADDRESS] CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) 
To further assess the potential benefits of reducin g residual  inflammation as determined by 
[CONTACT_244105]-CRP reduction, CANTOS (Canakinumab Anti-i nflammatory Thrombosis Outcome Study) 
was a randomized, double-blind trial of 3 SC doses of canakinumab (50, 150, and 300 mg) in 
10,061 patients with previous myocardial infarction (MI) and an hs- CRP level of ‚â•2 mg/L 
(Ridker 2017 ). The primary efficacy endpoint CANTOS was nonfatal MI, nonfatal stroke, or 
cardiovascular death. At 48 months the median reductions in hs-CRP levels compared to 
placebo were 26% (50 mg), 37% (150 mg), and 41% (300 mg) with all comparisons being 
statistically significant (p<0.0001). For the prima ry objective of CANTOS, the incidence rate 
of the predefined cardiovascular events wa s 4.[ADDRESS_296819] 
on the primary endpoint outcomes (hazard rati o [HR] vs placebo 0.85; p=0.[ZIP_CODE]; threshold 
p=0.[ZIP_CODE]). The [ADDRESS_296820] ratio vs placebo (HR vs placebo 
0.86), but did not reach significance versus placebo (p=0.[ZIP_CODE]; threshold p=0.[ZIP_CODE]).  In 
addition, the [ADDRESS_296821] reduces cardiovascular event rates independent of LDL-C ( Aday 2019 ). 
[IP_ADDRESS] CANTOS hs-CRP Threshold Analysis 
In the CANTOS trial, an additional prespecified secondary analysis of major cardiovascular events, cardiovascular mortality, and all-caus e mortality was performed in hs-CRP subgroups 
< 2.0 mg/L and ‚â• 2.0 mg/L  (Ridker 2018a ). During the CANTOS trial, patients who were 
treated with canakinumab and achieved an on treatment hs-CRP level < 2.0 mg/L had a 25% 
reduction in major cardiovascular events (adj usted HR 0.75, 95% confidence intervals [CI] 
0.66 - 0.85; p<0.0001).  Patients who had on treatment hs- CRP levels ‚â• 2.0 mg/L did not 
display a significant reduction in major cardi ovascular events (adjusted HR 0.90; 95% CI   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
27 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 28 of 142 0.79 - 1.02; p=0.11).  Similar significant reduc tions (31%) in cardiovascular mortality 
(adjusted HR 0.69; 95% CI 0.56 - 0.85; p=0.0004) a nd all-cause mortality (adjusted HR 0.69; 
95% CI 0.58 - 0.81; p<0.0001) were observed in patients who achieved the hs-CRP 
threshold, and no significant reductions in both cardiovascular and all-cause mortality were 
observed in patients who did not achieve the hs -CRP threshold. These results suggest that the 
reduction in hs-CRP levels during initial dos ing of canakinumab may provide a method to 
identify patients who may have the largest benefit from treatment. 
[IP_ADDRESS] CANTOS Patients with Moderate CKD 
Patients in the CANTOS trial had serial monit oring of eGFR, creatinine, the urine to albumin 
ratio (UACR), and renal and urinary AE monitoring ( Ridker 2018b ).  Of the 10,061 
CANTOS patients, 18.6% (1875 patients) ha d a baseline eGFR of < 60 ml/min/1.73 m2 
indicative of moderate CKD. Patients in this group had higher incidence rates of major 
vascular events compared with thos e patients who had a baseline eGFR ‚â• 60 ml/min/1.73 m2 
(6.92 vs 4.13 per 100 person years; p<0.0001). Among those patients with moderate CKD, 
treatment with canakinumab re duced the risk of major cardiovascular events by 18% (HR 
0.82; 95% CI 0.68 - 1.00; p=0.05).  However, the largest of these ef fects occurred in patients 
with moderate CKD who achieved on treatment hs-CRP levels < 2 mg/L after taking an initial dose of canakinumab (HR 0.68; 95% CI  0.53 - 0.86; p=0.0015). The primary endpoint 
of non-fatal myocardial infarction, non-fatal stro ke, or cardiovascular death in the placebo-
treated CKD patients had an event rate of 7.92 (per 100 person years) while the event rate in 
canakinumab-treated CKD patien ts who achieved an hs-CRP level below 2 mg/L was 5.35 
on , representing a 32% relative risk reduction between placebo and active which correlated 
to a number needed to treat (NNT) of eight.  
[IP_ADDRESS] Modulation of the interleukin-[ADDRESS_296822] and incidence rates of 
atherosclerotic events and all-cause mortality in CANTOS 
Based on the results and additional analyses from the hs-CRP/IL-6/IL-[ADDRESS_296823] discussion 
and the CANTOS trial described in the a bove sections, moving downstream from IL- 1Œ≤ 
inhibition to IL-6 inhibition may be a more effective target for the reduction of hs-CRP 
expression and ultimately improved atheroprotection ( Ridker 2016 ).  
In the CANTOS trial, 4833 patients had IL-6  levels measured before randomization and after 
treatment ( Ridker 2018c ). Compared with those allocated  to placebo, CANTOS participants 
receiving canakinumab who achieved on-treatment  IL-6 levels below the study median value 
of 1.65‚Äâng/L experienced a 32% reduction in major adverse cardiovascular events [MACE, 
multivariable adjusted hazard ratio (HRadj) 0.68, 95% confidence interval (CI) 0.56-0.82; 
P‚Äâ<‚Äâ0.0001], a 30% reduction in MAC E plus the additional endpoint of hospi[INVESTIGATOR_244071] (MACE+, HRadj 0.70, 95% CI 0.59-0.84;   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
28 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 29 of 142 P‚Äâ<‚Äâ0.0001), a 52% reduction in cardiovascular mortality (HRadj 0.48, 95% CI 0.34 -0.68; 
P‚Äâ<‚Äâ0.0001), and a 48% re duction in all-cause mortality (HRadj 0.52, 95% CI 0.40-0.68; 
P‚Äâ<‚Äâ0.0001) with prolonged treatment. In contrast, those with on -treatment IL-6 levels equal 
to or above 1.65 ‚Äâng/L after taking the first dose of canakinumab had no significant benefit for 
any of these endpoints. CANTOS provides proof of concept evidence in humans that 
modulation of the IL-[ADDRESS_296824] with canakinumab, associates with 
reduced cardiovascular event rates, independent of lipid lowering.  
1.1.2 Congestive Heart Failure, Primarily Heart Failure with Preserved Ejection 
Fraction (HFpEF) 
Cardiovascular disease (CVD) is  the primary driver of morbidi ty and mortality in chronic 
kidney disease (CKD) at all stages, ( US Renal Data System. 2002, Locatelli 2000 ). In end 
stage renal disease (ESRD), CVD mortality rate is up to 20 times higher than that of the 
general population ( Foley 1998 ). While the severity of rena l impairment is linked to CVD 
risk, accumulating evidence indicates that inflammation plays a key role in the progression of many forms of CKD and independently accounts for  at least part of the increased risk of 
cardiac events in CKD patients ( Go 2004 ). 
In cardiovascular disease, C-reactive protein (CRP) has been established as a pathognomonic 
measure of systemic inflammation, whose elevation connotes risk, and whose lowering confers benefit.  This relationship holds in the CKD population.  As recently reported in the 
SHARP trial (Study of Heart and Renal Protection ), which randomized 9270 patients with 
CKD to low-density lipoprotein cholesterol (L DL-C) lowering therapy or placebo, CRP was 
independently associated with both vascular  (atherosclerotic) and non-vascular CVD ( Storey 
2018).  In the AURORA trial ( A study to evaluate the Use of Rosuvastatin in subjects On 
Regular haemodialysis: an Assessment of survival and cardiovascular events ), 2773 patients 
on hemodialysis, CRP and albumin were signif icant predictors of CV events independent of 
traditional risk factors ( Solbu 2018 ). The CANTOS trial ( Canakinumab Anti-Inflammatory 
Thrombosis Outcomes Study ) evaluated the effects of an IL -1beta inhibitor, canakinumab, on 
CV events in patients with existing cardiovascu lar disease.  The majority of overall mortality 
benefit was driven by [CONTACT_244106], and the largest benefits accrued 
among those who had the most robust anti-inflammatory response, specifically these who 
achieved on-treatment CRP levels <2 mg/L ( Ridker 2018a ).The CRP lowering effect of 
canakinumab is mediated by [CONTACT_244107]- 1Œ≤ stimulation of IL -6 (Ridker 2016 ).  
Interleukin-6 is the major inflammatory cyt okine responsible for stimulating the hepatic 
synthesis of C-reactive protein ( Castell 1990 ). These data support the thesis that 
inflammation, systemically measured as increased CRP, is a surrogate for the effector 
molecule IL-6 which drives cardiovascular risk in CKD.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
29 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 30 of 142 As CKD progresses to end-stage, cardiovascular ri sk shifts from atherosclerotic (as studied 
in the trials noted above) to non-atherosclerot ic, specifically that of ventricular disease 
manifesting as arrhythmia, sudden cardiac deat h and heart failure, which has been termed 
‚Äúuremic cardiomyopathy‚Äù or ‚ÄúCardio -Renal Syndrome Type 4‚Äù ( Figure 1 , Herzog 2014 and 
Ronco 2008). 
Figure [ADDRESS_296825] revealed a relations hip between IL-6 driven inflammation, left 
ventricular hypertrophy and fibr osis, and an increase incidence in cardiovascular events in 
CKD ( Barreto 2010 , Rao 2005 , Pecoits-Filho 2002a) , with the level of inflammation as 
measured by [CONTACT_244108]-6 correlated with left ventricular hypertrophy as well as clinical 
outcomes ( Park 2002, Spoto 2015 ).   
The mechanisms by [CONTACT_244109]-6 driven inflam mation may be causal to the marked cardiac 
ventricular morbidity evident in advanced CKD populations can be described by [CONTACT_244110]: 
1. Hepcidin-independent direct IL-[ADDRESS_296826] on the cardiac ventricle, inducing 
myocyte hypertrophy and tissue fibrosis, possibly through a macrophage-induced, 
aldosterone-dependent mechanism via activation of cardiac fibroblasts ( Mel√©ndez 2010, Ma 
2012, Chou 2018 ).  In a more recent line of inve stigation, the Sponsor‚Äôs unpublished data 
further suggests that cardiac myocytes are susceptible to IL-6 mediated iron dysregulation 
which is exacerbated by [CONTACT_114273]-reperfusion (see Section [IP_ADDRESS] ).  Specifically, a 
synergistic increase in hepcidin expression by  [CONTACT_8668]-6 and bone morphogenic protein (BMP) is 
potentiated by [CONTACT_68413], and in aggregate notably increases cellular susceptibility to ischemia-reperfusion.   
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
30 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 31 of 142 B-type natriuretic peptide (BNP) is a horm one produced by [CONTACT_244111]. N-terminal 
(NT)-pro hormone BNP (NT-pro-BNP) is a non-a ctive prohormone that is released from the 
same molecule that produces BNP. Both BNP and NT-pro-BNP are released in response to 
changes in pressure inside the heart. N-Ter minal pro-B-type natriuretic peptide (NT-pro-
BNP) level predicts underlying heart disease in the general population. The association 
between NT-pro-BNP level and coronary artery disease (CAD) and left ventricular hypertrophy (LVH) was determined in 207 ambu latory patients with CKD not on dialysis 
therapy. NT-pro-BNP levels were elevated in  116 patients (56%), and 67 patients (33%) had 
experienced prior CAD events (myocardial in farction or revasculariz ation). After adjustment 
for glomerular filtration rate, cTnT level,  age, and diabetes, NT-pro-BNP remained an 
independent indicator of prior CAD events for patients with echocardiograms, NT-pro-BNP 
level predicted prior CAD events independent of LVH. NT-pro-BNP level elevation in 
asymptomatic patients with CKD reflects underlyi ng ischemic heart disease and hypertrophy 
independent of renal function in a population with anticipated high cardiac morbidity 
(DeFilippi 2005 ). The longitudinal Cardiovascular and Renal Outcome in CKD 2-4 Patients-
The Fourth Homburg Evaluation Study, prospectively studied 496 patients with CKD stages G2-G4. Left ventricular mass index, left atrial volume index, diastolic left ventricular function, and systolic left ventricular function we re assessed echocardiographically as well 
as levels of NT-pro-BNP.  During a mean follow-up of 4.5 years, 104 patients suffered decompensated heart failure or all-cause mortality, and 127 patents had atherosclerotic events or all-cause mortality.  NT-pro-BNP remained an independent predictor for both end 
points in multivariate analysis, whereas left ve ntricular mass index, left atrial volume index, 
and diastolic left ventricular function did not. This data confirmed th at NT-pro-BNP is an 
independent predictor of adverse outcomes in patients with CKD ( Understellar 2016 ). 
1.1.3 Functional Iron Deficiency (t he Anemia of Chronic Disease) 
Anemia is nearly universal among patients with advancing renal disease unless treated with erythropoiesis stimulating agents (ESAs) and supplemental iron ( Biggar 2017 ).  The etiology 
of this anemia is that of EPO deficiency  alongside IL-6 driven inflammation, which 
stimulates the production of the protein hepcidin ( Wrighting 2006, Babitt 2012) . Hepcidin, a 
peptide hormone which is mainly synthesized in the liver, reduces extracellular iron in the 
body by [CONTACT_244112]: 1) it lowers dietary iron absorption by [CONTACT_244113] (enterocytes); 2) it reduces iron exit from macrophages, the main 
site of iron storage; and 3) it re duces iron exit from the liver ( Reichert 2017 , Sun 2012 ).  This 
pathophysiologic state represents an inefficiency of erythropoiesis, as evident by [CONTACT_244114]-synthetic capacity by 
[CONTACT_10521], in order to maintain serum hemoglobin at an acceptable value ( Mercadal 2012 ).   
These high doses of ESAs and the maintenance of a high ferritin level are associated with   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
31 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 32 of 142 increased risk of cardiovascular complications, the former of which is highlighted by [CONTACT_244115]‚Äôs boxed warning on ESA product labelin g advising conservative serum hemoglobin 
targets.  Furthermore, the Sponsor‚Äôs unpublished data describes a novel, intermediate hormonal mechanism which may be causal in dr iving this observed erythropoietin-mediated 
cardiac injury. 
Randomized controlled trials of ESA therapy studying normalization of Hb have failed to 
demonstrate any beneficial effect on cardiovasc ular outcomes or death. Instead, these trials 
have indicated some potential harmful effects ( Singh 2006 , Besarab 1998 ). On the basis of 
this evidence, the recommended Hb initiati on level for ESA use in the Kidney Disease 
Improving Global Outcomes (KDIGO) guidelines has been modified from 11 to <10 g/dL 
with the statement that it is no longer recommended to maintain Hb values above 11.5 g/dL 
(KDIGO 2012). The suggested target level by [CONTACT_244116] 10-
12 g/dL and recommend not letting Hb fall below 10 g/dL ( Locatelli 2013 ). In addition, the 
FDA and EMA recommend that ESA should be used  at the lowest possible dose to control 
anemia and avoid blood transfusions; see Information for Healthcare Professional: 
Erythropoiesis Stimulating Agents (ESA) US FDA 2011. 
Pre-clinically, IL-[ADDRESS_296827] the described derangements in iron handling 
(MacDougall 2005, Sun 2012), and clinically anti-IL-[ADDRESS_296828] been shown to 
reduce serum hepcidin and increase serum hemo globin in Multicentric Castleman‚Äôs Disease, 
Rheumatoid Arthritis, as well as advanced pulmonary malignancy ( Song 2010, Song 2013, 
Bayliss 2011 ).  In hemodialysis, the Sponsor‚Äôs investigation ([STUDY_ID_REMOVED]) has shown that 
neutralizing IL-[ADDRESS_296829] re lationship between ESA dose and cardiovascular 
complications, as well as the risk of iron ove rload with chronic administration of IV iron, the 
Sponsor believes that Ziltivekimab would fulfill a clear, present and pervasive need in the 
treatment of anemia in the CKD setting. 
1.1.4 Malnutrition-Inflammation-Cachexia Syndrome including 
hypoalbuminemia 
Persistent inflammation in CKD is also one  of the key players in the development of 
malnutrition/protein-energy wasting (PEW), which led to the description of the malnutrition-
inflammation-cachexia syndrome (MICS) in CKD ( Kalantar-Zadeh 2003, Kalantar-Zadeh 
2005).  Hypoalbuminemia is strongly associated w ith mortality in dialysis patients ( Kalantar-  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
32 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 33 of 142 Zadeh 2005b ) as well as non-dialysis dependent CK D, which when included as part of a 
‚Äúmalnutrition inflammation score‚Äù with IL -6 and CRP strongly predicts 36-month mortality 
(Jagadeswaran 2018 ). Although historically hypoalbuminemia has been attributed to 
malnutrition, the recent lack of effect of ora l nutritional supplementation on serum albumin 
strongly suggest that inflammation is the causal factor in hypoalbuminemia, especially when 
placed in the context of a direct link between  IL-6 and hepatic albumin synthesis, and 
clinically, anti-IL-6 therapy can raise serum albumin in non-renal patients ( Benner 2018, de 
Mutsert 2009, Ohsugi 2007 ). At this time, no therapy is indicated to improve 
hypoalbuminemia in patients with CKD. 
1.2 Description of Ziltivekimab 
Ziltivekimab is an extended half-life anti-IL-6 antibody ( human IgG1Œ∫  anti-human IL-6 
monoclonal antibody) with three amino acid substitutions (‚ÄúYTE‚Äù) in the CH2 region of the 
Fc domain designed to decrease clearance, and thereby [CONTACT_244104]. Additional 
information about the mechanism and structure  of Ziltivekimab can be found in the 
Ziltivekimab Investigator‚Äôs Brochure  (IB).  
Alleviation of inflammatory anemia with anti-IL-6 therapy comes from published work regarding the use of said therapy in humans in non-renal inflammatory conditions. Tocilizumab ([COMPANY_002]) and clazakizumab (Alder Biopharmaceuticals) have both shown ability 
to raise hemoglobin in rheumatoid arthritis, Castleman‚Äôs disease and advanced malignancy 
(Song 2010, Song et al 2013, Bayliss 2011) .  By [CONTACT_244117], the ad ministration of tocilizumab 
(anti-IL-6 receptor antibody) reverses signs of inflammation, improves iron availability, and increases hemoglobin in Castleman ‚Äôs patients . 
Although anti-IL-[ADDRESS_296830] not been teste d in dialysis patients to date, published and 
Sponsor‚Äôs unpublished data in a large prevalent dialysis population documents a correlation 
between serum IL-6 levels and the degree of ESA hypo-responsiveness (i.e., erythropoietin dose requirement divided by [CONTACT_244118]) ( Won 2012 and see Section 2  of 
the Ziltivekimab IB). 
However, the influence of IL-6 is not universal, and appears over-represented in a specific, 
genotypi[INVESTIGATOR_244072].  Based on non-clinical study and retrospective review 
of dialysis populations (data on file), it appear s a genotypic variation in the iron-control 
system of mammalian cells can render tissues more or less susceptible to IL-6 based 
inflammation  and dictate the influence of this inflammation on clinical outcomes ( Figure 2 ). 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
33 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 34 of 142 Figure 2 A model for the influence of genetic variation on IL-6 ‚Äìmediated cellular 
iron handling   
 
 
Matriptase-2 (TMPRSS6) = serine protease suppressor of HA MP (hepcidin gene) mRNA expression; 736V = normal allele; 
736A = risk allele; BMPR = BMP r eceptor; IL-6R = IL-6 receptor; FPN = ferr oportin; Fe = iron 
 
1.3 Summary of Relevant Nonclinical Experience with Ziltivekimab 
For information regarding nonclinical pharmacol ogy, pharmacokinetics in animals, and 
nonclinical toxicology and safety, please refer to the Ziltivekimab IB . 
1.4 Summary of Relevant Clinical Experience with Ziltivekimab 
1.4.1 Phase 1 Study in Rheumatoid Arthritis Patients (D4430C00001) 
This study was a Phase 1, double-blind, placebo-controlled single ascending dose study in 
rheumatoid arthritis patients (Study D4430C00001) which completed in February 2014.  This study was a dose-escalation from 30 mg, with provisional doses of 90, 270, and 600 mg thereafter.  After 4 patients we re enrolled (3 receiving Ziltivekimab 30 mg IV (single dose) 
and 1 receiving placebo), the study was termina ted due to difficulties with recruitment.  
Further details surrounding this study can be found in the Ziltivekimab IB. 
Less susceptible to IL-6  
HAMP
TMPRSS6
A/G or G/G
BMPR 
 IL
- 
6R
IL
- 
6 Low 
Fe
Fe
IL 
-
6 High  
Fe
Fe
Fe
Fe
Matriptase
 -
2 ( 
TMPRSS6  
) 736A
HAMP 
TMPRSS6  
A/A 
BMPR 
 IL 
L- 
6R 
Fe 
Fe 
Fe 
Matriptase  
- 
2 ( 
TMPRSS6  
) 736V  
Fe 
Fe 
FPN 
More susceptible to IL-6  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
34 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 35 of 142 1.4.2 Phase 1 Study in Patients with CKD (COR-001-SC1) 
This study was a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Cohort Dose-
Escalation Study in Patients with CKD to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of Ziltiv ekimab. The study population had moderate-to-
severe CKD (i.e., eGFR 20-60 mL/min/1.73 m
2) who had serum CRP levels >2 mg/L over 
2 consecutive measurements. The primary objectiv e evaluated the safety of single SC doses 
of Ziltivekimab (5, 15, 50 and 100 mg). The main  secondary objective evaluated single-dose 
PK of SC Ziltivekimab and the effects of Zi ltivekimab on CRP and serum amyloid A (SAA). 
After SC administration, Ziltivekimab concentr ations reached peak levels by [ADDRESS_296831] dose in all patients. Ziltivekimab concentrations increased in a dose dependent 
manner. Terminal slopes (half-life) appeared simi lar for [ADDRESS_296832] dose cohort (50 mg) confounded the interpretation for that dose. One patient in the 50 mg dose cohort had levels 2- to 3-fold higher than the other two patients so that it appeared that the latter patients displayed a less than dose proportional increase, while the former showed a greater than dose proportional increase in Ziltivekimab serum levels.  
Mean hs-CRP levels were comparable and elev ated at Baseline across placebo and the 
Ziltivekimab treatment groups suggesting systemic inflammation.  Figure 3 presents the 
percentage of patients who achieved an hs-CRP level of < 2.0 mg/L from Baseline to Week 
32. A consistent decrease in hsCRP levels was observed in the Ziltivekimab dose groups throughout the first eight weeks post randomization, while levels in the placebo group increased over time. 
Figure 3 Percentage of CKD patients trea ted with Ziltivekimab or Placebo who 
achieved an hs-CRP level of < 2.0 mg/L from Baseline to Week 32  
 
50 mg 15 mg 5 mg Placebo0%20%40%60%80%100%hsCRP Responder Rate
(on treatment hs CRP < 2  mg/L)100% 100%
33%  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
35 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296833] (n=3) was upper respi[INVESTIGATOR_13521] y tract infection. Other than one report of 
diarrhea, none of the other AEs were consider ed related to the study product. During the 
study, one subject on placebo reported an SAE (acute cardiac failure), there were no deaths 
and no subject discontinued the study as of February 01, 2018. 
1.4.3 Phase 1/2 Study in CKD Patients on Hemodialysis (COR-001-01) 
This study was a Phase 1/[ADDRESS_296834] neutralizing 
antibodies. Further details of this study may be found in the IB.  
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
36 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296835] Patients  
 
Abbreviations:  hs-CRP = high-sensitivity C- reactive protein; N = number of subjects 
Note: Ziltivekimab (2 mg, 6 mg or 20 mg IV) Q2 weeks; Data from Pharmacodynamic Analysis Population. 
Note: After checking the data normality, the pa rameter was shown as Median (Q1/Q3). 
Source: Protocol No: COR-001-01 Final Analysis 
 
There was a greater incidence of Treatment Emerg ent Adverse Events (TEAE) in each of the 
Ziltivekimab groups than in the placebo group, there was not a clear dose response. The [ADDRESS_296836] incidence in the trial were reported in this treatment 
group (congestive cardiac failure and dyspnea which each occurred in 4 patients).  
Serious adverse events (SAEs) occurred at a higher rate in the [ADDRESS_296837] incidence of SAEs (7 
patients reporting a total 14 SAEs), and all 4 of th e congestive cardiac failure events in the 6 
mg group were considered serious. None of the SAEs in any group were assessed as treatment related. There were 4 patients who had SAEs with a fatal outcome; sepsis (Patient 
) and sudden cardiac death (Patient )  in the 6 mg group and sepsis ( ) and 
cardiac arrest ( ) in the 20 mg group. None of the deaths were attributed to study drug; 
more information on the Safety results fr om study COR-001-01 can be found in the 
Investigator Brochure.        
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
37 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 38 of 142 1.4.4 Conclusions on Ziltivekimab Treatment of Anemia in CKD 
Ziltivekimab is a potent and highly selective fully-human anti-IL-6 antibody in development 
for the treatment of anemia in CKD patients . Ziltivekimab has shown marked reductions in 
hs-CRP levels (inflammation) within the first weeks of administration and continuing 
throughout the treatment period. In summary, the clinical evidence presented here supports investigating Ziltivekimab as a product to  reduce hs-CRP based inflammation and an 
ultimate reduction in anemia-associated CVD in the proposed patient population.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
38 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296838] a significant reduction in hs-CRP with acceptable increases in LDL-C or triglycerides and without clinically meaningful reductions in neutrophils and platelet counts. Do ses to be tested will be 7.5 mg, 15 mg and 
30 mg subcutaneous monthly compared to placebo for six months.   
2.1 Primary objective: 
To evaluate the effects of Ziltivekimab compared to placebo on markers of inflammation (i.e. 
hs-CRP). 
2.2 Secondary objectives: 
To evaluate the effects of Ziltivekimab comp ared to placebo on markers of inflammation and 
cardiovascular risk: serum amyl oid A (SAA) and fibrinogen. 
2.3 Pharmacokinetic objectives: 
To evaluate the pharmacokinetics (PK) a nd PK-Pharmacodynamic (PK-PD) modeling of 
Ziltivekimab following multiple doses at three different levels. 
2.4 Safety objectives: 
To evaluate the safety of three dose level s of Ziltivekimab compared to placebo. 
2.5 Exploratory objectives:   
To evaluate the effects of Ziltivekimab compared to placebo on markers of anemia 
(hemoglobin). 
To evaluate the effects of Ziltivekimab comp ared to placebo on markers of inflammation-
malnutrition (i.e. albumin). To evaluate the effects of Ziltivekimab comp ared to placebo on marke rs of cardiovascular 
risk (i.e. N-terminal prohormone-B-typ e natriuretic peptide [NT-pro-BNP]). 
To evaluate the effects of Ziltivekimab co mpared to placebo on additional markers of 
cardiovascular risk (suppression of tumorigenicity 2 [ST2]). To evaluate the effects of Ziltivekimab comp ared to placebo on markers of atherosclerosis 
risk: LDL-C, triglycerides, ApoB, ApoA1, ApoB/ApoA1, lipid profile by [CONTACT_244096] (NMR) spectroscopy, and Lp(a).    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
39 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 40 of 142 To evaluate the effects of Ziltivekimab compared to placebo on markers of kidney function, 
(i.e. cystatin C, estimated GFR) and kidney dama ge, (i.e. urine albumin-to-creatinine ratio 
[UACR]). 
To determine Ziltivekimab trough drug levels following multiple Ziltivekimab doses at three 
different dose levels. 
To evaluate the effects of three dose levels of Ziltivekimab compared to placebo on patient 
reported outcomes (PRO): Patient-Reported Outcomes Measurement Information System 
(PROMIS¬Æ) Fatigue 13a short form, selected items from the PROMIS fatigue item bank, the Optum SF-36 v2¬Æ Health Survey, a Corvidia PRO, the PROMIS interest in sexual activity 
item, the patient global impression of change (P GIC), patient global impression of severity 
(PGIS), and the EQ-5D-5L.  
To evaluate the psychometric properties of the PR OMIS Fatigue 13a short form and selected 
items from the PROMIS fatigue item bank, and the Corvidia electronic PRO (ePRO) items in 
CKD patients. To evaluate the effects of Ziltivekimab on systemic iron availability:  transferrin saturation 
(TSAT), reticulocyte hemoglobin content (C Hr) and total iron binding capacity (TIBC), 
systemic iron stores (serum ferritin), serum iron and systemic iron regulation (serum hepcidin). 
To evaluate the effects of Ziltivekimab comp ared to placebo on mar kers of cardiovascular 
risk (i.e. NT-pro-BNP) in patients with baseline NT-pro-BNP > 250 pg/mL. To evaluate the effects of Ziltivekimab compared to placebo on markers of anemia in patients 
with baseline hemoglobin < 11 g/dL.  
To evaluate the effects of Ziltivekimab comp ared to placebo on markers of inflammation-
malnutrition (i.e. albumin) in patients with baseline albumin < 4.0 g/dL.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
40 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 41 of 142 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan: Description 
This is a randomized, double-blind, placebo-controlled trial designed to evaluate the 
efficacy, safety, and pharmacokinetics of Ziltivekimab at three dose levels (7.5 mg, 15 mg or 30 mg) compared to placebo in patients with stage 3-[ADDRESS_296839] evidence of inflammation with high cardiovascular risk.  
Patients will undergo a Screening Period of up to 14-days during which inclusion and 
exclusion criteria will be evaluated. Patients who meet all inclusion criteria and no exclusion criteria will be randomized to one of three Ziltivekimab dose levels (7.5 mg, 15 
mg or 30 mg) or placebo for a 24-week Treatment Period. Patient randomization will be 
stratified by [CONTACT_244097] ( ‚â•11 or <11 g/dL) and CKD stage (3, 4 or 5).  
Approximately 240 patients will be randomized 1:1:1:1 (60 per group) into the trial. All 
patients must meet the inclusion/exclusion criteria. After the Screening Period, randomized patients will be dosed every 28 days out to Week 21. The primary, secondary and exploratory 
endpoints will be analyzed at 13 weeks of dosing and then followed for additional exploratory efficacy analyses through Week 24, and then selected efficacy endpoints and safety assessments will evaluated in the Follow-up Period Week 25 though Week 32 (Figure 5 ). The primary, secondary, and exploratory e ndpoint evaluation will take place at the 
end of Week 13, and the additional exploratory evaluations will take place at the End of 
Treatment (Weeks 23 and 24).    
The patient will be randomized on Day [ADDRESS_296840] dose of study drug should be 
administered after all assessments are conducted.  Doses of study drug will be administered every 28-days for a total of 6 treatments (Weeks 1, 5, 9, 13, 17 and 21). Study visits will follow the schedule of events ( Table 2 ). 
3.1.1 Pharmacokinetic and PK-PD Modeling 
x Serum trough levels (C
min) of Ziltivekimab will be measured at all visits. On dosing 
Week 1, 5, 9, 13, 17, and 21, trough PK samples to be collected within approximately -0.5 h pre-dose.  Single PK blood samples will also be collected on Weeks 
2, 4, 7, 23, 24/ET, 28, and 32/ET around the same  time as the pre-dose samples were 
collected on previous dosing visits.  
x The total IL-6 AUC will be described. 
x The relationship between trough Ziltivekim ab levels and primary pharmacodynamic 
endpoints, specifically total plasma IL -6 and hs-CRP, will be described.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
41 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 42 of 142 3.1.2 Safety Endpoints 
x Proportion of patients with AEs, SAEs, seve re hematologic AEs, severe non-hematologic 
AEs, and AEs leading to discontinuation. 
x Proportion of subjects with thrombolysis in my ocardial infarction (TIMI) major bleeding 
event. 
x Description and frequency of events of special interest by [CONTACT_1570]: 
o Serious infections. 
o Severe injection-related reactions. 
o Gastrointestinal perforations. 
o Hypersensitivity reaction during study drug administration.  
o Anaphylaxis occurring at any time, even if considered unrelated to the study drug. A 
CRF for the collection of the details of such reactions will be available in the 
electronic data capture (EDC) system. 
o Neutrophil <500/mm3 (severe) or neutrophil <1000/mm3 (severe) with evidence of 
concurrent infection. These events will be separately summarized by [CONTACT_244099]. 
o Thrombocytopenia (platelet count <50,000/mm
3 [severe]) or platelet count 
<75,000/mm3 (moderate) with evidence of concurrent TIMI major bleeding. These 
events will be separately summarized by [CONTACT_244099]. 
o Malignancies 
x Description of additional safety assessments by [CONTACT_244099]: vital signs, 
electrocardiogram (ECG), clinical laborator y, and anti-drug antibodies (binding and 
neutralizing). 
3.1.3 Pharmacodynamic Endpoints 
[IP_ADDRESS] Primary 
x Difference in percent change in hs-CRP lev els from Baseline (average of the hs-CRP 
value prior to randomization and Day 1) to  Week 13 between each active group and 
placebo. 
[IP_ADDRESS] Secondary  
All secondary and exploratory analyses will be performed with the Intent-to-Treat (ITT) 
population.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
42 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 43 of 142 x Difference in change in SAA from Baseline  to Week 13 between each active group and 
placebo. 
x Difference in percent change in fibrinogen from Baseline to Week 13 between each 
active group and placebo. 
[IP_ADDRESS] Exploratory 
x Difference in percent change in hs-CRP levels from Baseline to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in percent change in serum NT-pro-BNP from Baseline (average of the NT-
pro-BNP value prior to randomization and Day 1) to Week 13 and to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in change in SAA from Baseline to End of Treatment (Weeks 23 through 
24) between each active group and placebo. 
x Difference in percent change in fibrinogen  from Baseline to End of Treatment (Week 
24) between each active group and placebo. 
x Difference in change in hemoglobin from Base line (average of the two most recent 
hemoglobin values prior to randomization and Day 1) to Week 13 and to End of 
Treatment (Weeks 23 through 24) betw een each active group and placebo. 
x Difference in change in serum albumin from Baseline (average of the two most recent 
serum albumin values prior to randomization and Day 1) to Week 13 and to End of Treatment (Weeks 23 through 24) betw een each active group and placebo. 
x Proportion of patients achieving hs-CRP response at Week 13 and to End of Treatment 
(Weeks 23 through 24), defined as hs-CRP <2.0 mg/L in each active group and placebo. 
x Difference in change in ST2 from Baseline to Week 13 and to End of Treatment (Week 
24) between each active group and placebo. 
x Difference in percent change in Lp(a) from Baseline to Week 13 and to End of 
Treatment (Weeks 23 through 24) betw een each active group and placebo. 
x Difference in percent change in LDL-C, triglycerides, ApoB, ApoA1, ApoB/ApoA1, 
and lipid profile by [CONTACT_244119] 13 and to End of 
Treatment (Weeks 23 through 24) be tween each active group and placebo. 
x Difference in change of creatinine base d eGFR and cystatin C-based eGFR from 
Baseline to Week 13 and to the End of Tr eatment (Weeks 23 through 24) between each 
active group and placebo.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
43 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 44 of 142 x Difference in change of UACR from Baseline  to Week 13 and to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in change of the total fatigue score (PROMIS Fatigue 13a short form and 
selected items from the PROMIS Fatigue item bank) from Baseline to Week 13 and to 
End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change of the PROMIS interest in sexual activity item from Baseline to 
Week 13 and to End of Treatment (Week 24) between each active group and placebo. 
x Difference in change of the Corvidia ePRO items from Baseline to Week 12 and to End 
of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change of the PGIS index from Baseline to Week 12 and to End of 
Treatment (Week 24) between each active group and placebo. 
x Descriptive analyses of the PGIC index at Weeks 5, 13 and End of Treatment (Week 24) in each active group and placebo. 
x Difference in change of the Optum SF- 36 v2¬Æ Health Survey physical component 
summary (PCS), mental component summary (MCS) and domain scores from baseline 
to Week 13 and to End of Treatment (Week s 23 through 24) between each active group 
and placebo. 
x Difference in change of the EQ-5D-5L index from Baseline to Week 12 and to End of 
Treatment (Week 24) between each active group and placebo. 
x Evaluation of the psychometric properties of the PROMIS Fatigue 13a short form and 
selected items from the PROMIS Fatigue item bank and the Corvidia ePRO items in 
CKD patients ‚Äì to be described in a PRO psychometric analysis plan. 
x Descriptive analyses by [CONTACT_244120], genomic and transcriptomic analysis. 
x Difference in change in TSAT from Baseline to peak level, Week 13 and End of Treatment (Weeks 23 through 24), betwee n each active group and placebo. 
x Difference in change in CHr from Baseline to peak level, Week 13 and to End of 
Treatment (Week 24) between each active group and placebo. 
x Difference in change in TIBC from Baseline to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change in serum ferritin from Baseline to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
44 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 45 of 142 x Difference in change in serum iron from Ba seline to Week 13 and to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in change in serum hepcidin from Baseline to Week 13 and to End of 
Treatment (Week 24) between each active group and placebo. 
x Difference in percent change in serum NT-pro-BNP from Baseline to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo in 
patients with baseline NT-pro-BNP > 250 pg/mL. 
x Difference in change in hemoglobin from Baseline (average of the two most recent hemoglobin values prior to randomization and Day 1) to Week 13 and to End of 
Treatment (Weeks 23 through 24) between each active group and placebo in patients with 
baseline hemoglobin < 11 g/dL. 
x Difference in change in serum albumin from Baseline (average of the two most recent 
serum albumin values prior to randomization and Day 1) to Week 13 and to End of 
Treatment (Weeks 23 through 24) between each active group and placebo in patients with 
baseline albumin < 4.0 g/dL. 
     Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
45 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 46 of 142 3.2 Study Schematic  
Figure 5 Study Flow 
 
Ziltivekimab Dose Level 1, 2 or 3 (N=180); N=60 in each level  
  
 
Placebo (N=60)  
 
 Screening Treatment Period Safety F/Up 
Visit 
Number -2 -1 1 2 3 4 5 6 7 8 9 10 11/ET 12 13/ET  
Visit Day 
Window -14 -7 1 8 22 29-35  43-49  57-63  85-91  113-
119 141-
147 155-
161 162-
168 190-196  218-224  
Visit 
Window  rr2 1 r2 r2           
Visit 
Week -2 -1 1 2 4 5 7 9 13 17 21 23 24/ET 28 32/ET 
 
3.3 Blinding and Randomization 
3.3.1 Randomization 
Treatments will be assigned to randomized pa tients via an interactive web-response system 
(IWRS).  Patients (N=240) will be randomized in 1:1:1:1 ratio to Ziltivekimab Dose #1 (7.5 
mg), Ziltivekimab Dose #2 (15 mg), Ziltivekimab Dose #3 (30 mg) or matching Placebo, as 
they meet all entry criteria. Patients will be stratified by [CONTACT_244097] ( ‚â•11 or <11 
g/dL) and CKD stage (3, 4 or 5).  Note that CKD stage is stratified into two categories: (1) stage 3 and (2) stages [ADDRESS_296841] Research Organiza tion (CRO) clinical operational personnel will 
be blinded to the treatment assignment (see Section 12.2  for details). Ziltivekimab and 
matching placebo will be provided as a liquid for subcutaneous injection.  
The randomization list will be generated by a CRO statistician not otherwise involved in the 
study. 
3.3.3 Unblinding 
In case of a medical emergency or medical si tuation in which the treatment assignment is 
necessary for proper patient management, the Investigator may obtain the treatment   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
46 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296842] of three periods:  Screening, Treatment Period, and Safety Follow-
Up Period. The total study duration for an individual patient will be approximately 8-9 months.  The study period durations are as follows: 
Screening Period: up to 2 weeks [Days -14 to -1]  
x Starts with the first date that Initial Screening procedures were performed. The 
first procedure also defines the initial screening visit date 
Treatment Assessment Period: 24 weeks [Week 1, Day 1 through Week 24, ] 
x Starts with the first administration of study drug/randomization (Day 1) 
Safety Follow-Up Period: 8 weeks [Weeks 25 through 32] 
x Safety period starts 4-weeks after last treatment dose 6.  
3.5 Discussion of Study Design, Including Choice of Control Arm  
The study is a randomized, double-blind, plac ebo-controlled trial.  Randomization and 
double-blinding are being used to minimize bias. The treatment duration (Weeks 1 through 
24) was chosen as the shortest duration needed to evaluate the pharmacodynamic effect of 
said doses on the proposed inflamma tory, hematologic and cardiovascular
 endpoints.  Sample 
size calculations were performed for severa l pharmacodynamics endpoints and these are 
presented in Section 11.1.  
3.5.1 Study Population and Control Arm 
As there are currently no drugs approved for the treatment of functional iron deficiency and 
reduction of hs-CRP, there are no opti ons for an active comparator.  
The study is being conducted in the tar get population because the pharmacodynamic 
endpoints (inflammation, functional iron deficiency, and increased cardiovascular risk) cannot be evaluated in healthy volunteers.  
3.5.2 Rationale for Dosing and Length of Safety Evaluation 
Inhibition of free IL-6 greater than 90% is needed to achieve biologic effect, because growth 
factors and soluble cytokines in general are able to elicit signaling with receptor occupancies 
of less than 10%.  A basic logarithmic dose es calation scheme was used after modeling of   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
47 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 48 of 142 IL-6 binding and the PK-PD (hs-CRP) relationshi p from the concluded Phase 1 trial in RA 
patients (Study D4430C00001).  Based on the c learance of Ziltivekimab (dictated by [CONTACT_941] 
‚ÄúYTE‚Äù Fc mutation),  the duration of safety monitoring and follow-up for PK, IL-6, and 
antibody testing to [ADDRESS_296843] measure of IL-6 function (specifica lly hs-CRP genes are 
induced by [CONTACT_8668]-6). The inflammatory biomarker hs-CRP has been shown to be a strong 
component in the prediction of cardiovascular ri sk to an extent approximately equivalent to 
total and high-density cholesterol (HDL) levels.  Further data support that hs-CRP levels while on statin therapy are a large predictor of cardi ovascular risk to a similar extent to those 
seen with LDL ( Ridker 2016 ).  However, CRP has a short circulating half-life of 
approximately [ADDRESS_296844] of CRP production is downstream regulated by [CONTACT_8668]-6 expression 
which is itself regulated by [CONTACT_244121]-1, specifically the inhibition of 
the IL- 1Œ≤-producing NOD-like receptor family pyrin domain containing 3 
inflammasome.  Thus, hs-CRP levels can be c onsidered downstream surrogate biomarkers of 
both IL-6 and IL-1 expression when evaluating compounds which regulate their specific 
respective actions. Inhibition of IL-6 or IL -1 expression for the ultimate outcome of a 
reduction in circulating hs-CRP levels has been undertaken in several recent clinical studies 
(Ridker 2016 ).  
The secondary endpoints include evaluations of fibrinogen and serum amyloid A (SAA). 
Fibrinogen is an acute phase reactant and a med iator of coagulation a nd therefore a marker of 
cardiovascular risk and a predictor of future cardiovascular risk ( Ridker 2012 ). The 
difference in percent change in fibrinogen w ill be evaluated from Baseline to Week [ADDRESS_296845] cardiovascular risk in humans ( Shridas 
2019). The difference in change in SAA will be evaluated from Baseline to Week 13 between 
each active group and placebo. 
The exploratory endpoints include eval uations of NT-pro-BNP, ST2, albumin and 
hemoglobin. Serum NT-pro-BNP is a marker of cardiovascular risk and a predictor of future 
cardiovascular risk. Percent change in serum NT -pro-BNP will be evaluated from Baseline to 
Week 13 and to End of Treatment betwee n each active group and placebo. Suppression of   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
48 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 49 of 142 tumorigenecity 2 (ST2) is a prognostic marker for heart failure with preserved and reduced 
ejection fraction. ST2 is a member of the interleukin 1 receptor family, also known as 
interleukin 1 receptor-like 1 (IL1RL-1). High  circulating level of ST2 is associated to 
increased cardiovascular disease mortality and markers of metabolic dysfunction in subjects 
with atherosclerotic disease.  
Serum albumin was selected as an additional exploratory endpoint because it is also closely 
negatively correlated with inflammation in the CKD population and is therefore also being 
analyzed as a marker of inflammation. Change s in serum albumin will be evaluated from 
Baseline to Week [ADDRESS_296846] action of IL-6 there is overproduction o f ‚Äúthe 
master iron regulator‚Äù hepcidin, a protein which prohibits cellular iron transport via 
degradation of ferroportin, the only known iron export channel in humans. This elicits a 
functional iron blockade that leads to anemia. Ch anges in serum hepcidin will be evaluated 
from Baseline to Week 13 and to End of Trea tment between each active group and placebo.  
Additional hematologic pharmacod ynamic endpoints chosen include TSAT, CHr, TIBC, 
iron, and ferritin. These endpoints are intended  to evaluate the effects of reducing 
inflammation on functional iron deficiency anemia.  It is hypothesized that CHr will increase 
as iron is released from tissue stores. TSAT is  also expected to in crease over time as more 
iron is mobilized, until iron is utilized for er ythropoiesis (reflected in rising hemoglobin). 
Supportive pharmacodynamic e ndpoints include LDL-C, triglycerides, ApoB, ApoB/A1, and 
Lp(a). Biomarkers for CKD will be evaluate d including cystatin C, creatinine, and UACR. 
Finally, inflammation is known to affect systemic symptoms, notably fatigue and skeletal muscle strength; assessments will be made for selected items from the  PROMIS Fatigue and 
13a short form, Optum SF-36 v2¬Æ Health Survey, Corvidia ePRO, PGIS, PGIC, and EQ-5D-5L. 
3.5.4  Rationale for the Dose Regimens 
The main goal of Ziltivekimab dosing in the pla nned Phase 1/2 CKD patient study is to attain 
and maintain serum Ziltivekimab concentrations sufficient for ‚â•90% IL-6 binding over the 
treatment period, with a secondary goal of re ducing hs-CRP to below 2 mg/L while keepi[INVESTIGATOR_244073] 20-fold below the no adverse effect level (NOAEL) 
observed in primates.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
49 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 50 of 142 [IP_ADDRESS] Pharmacokinetic modeling 
To date, the Ziltivekimab clinical program is comprised of [ADDRESS_296847] of these studies (Study COR-001-01), 
patients with ESRD were administered intr avenous (IV) infusions of study drug every 2 
weeks for a total of 6 doses. Ten patients per cohort were randomized in a 1:4 ratio to 
placebo or Ziltivekimab (2, 6, and 20 mg).   
In the second study (Study COR-001-SC1), patien ts with CKD were administered single 
subcutaneous (SC) doses of study drug.  Four patients per cohort were randomized in a 1:3 
ratio to placebo or Ziltivekimab (5, 15, and 50 mg).   
The PK parameters are generally consistent with  those expected for a monoclonal antibody.  
Absolute bioavailability (F) of SC administered Ziltivekimab is 69%, and the mean time of 
occurrence for peak serum Ziltivekimab concentrations (t max) after SC dosing ranged from 8 
to 15 days, with an absorption half-life of 3 days. Terminal elimination half-lives (t 1/2,z) 
differed between the ESRD patients (mean t 1/2,z ranging from 38 to 44 days) and CKD 
patients (mean t 1/2,z ranging from 48 to 56 days).  While these results suggest that the rate of 
Ziltivekimab elimination may increase with decreasing renal function, a prior observation in 
rheumatoid arthritis patients that Ziltivekimab cl earance is much slower  than the glomerular 
filtration rate implies that the apparent elimin ation rate difference is not due to renal function 
per se, but more likely othe r physiological changes that accompany decreased renal function. 
[IP_ADDRESS] Correspondence of proposed doses to those used in prior clinical studies 
Based on the clinical PK for Ziltivekimab described above, especially the F of 69.3% for SC dosing, the correspondence of proposed SC doses can be derived. Table 1  provides a 
summary of the SC doses that would correspond to the Ziltivekimab doses used in prior 
studies. From this perspective, the proposed 7.5 and 15 mg q4w x 6 regimens are well within 
the range of exposures considered safe in the prior clinical study, and the proposed 30 mg 
q4w x 6 regimen is less than the exposure a ssociated with adverse changes in laboratory 
parameters in the prior clinical study. 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
50 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 51 of 142 Table  1 Summary of IV doses used in Study COR-001- 01 with SC doses that 
represent corresponding exposure 
 IV Dosing SC Dosing 
COR-001-01 
Dose  q2w 
(mg)  q4wa 
(mg)  Cumulative Doseb 
(mg)  q4wc 
(mg)  Cumulative Dosec 
(mg)  Monthly Dosed 
(mg) 
2 mg q2w x12 2 4 24 5.8 34.6 5.8 
6 mg q2w x12 6 12 72 17.3 103.9 17.3 
20 mg q2w x12 20 40 240 57.7 346.3 57.7 
Abbreviations:  IV, intraven ous;  SC, subcutaneous;  q2w, every 2 weeks;  q4w, every 4 weeks. 
a Cumulative dose administered every 4 weeks, i.e., the total of 2 q2w doses given within a 4 week period. 
b Cumulative dose over the duration of the study, i. e., the total of 12 q2w doses given during the study. 
c Corresponding SC dose, assuming bioavailability (F) of 69.3%. 
d Monthly SC dose for 6 monthly doses that corresponds  to the SC cumulative dose, i.e., SC cumulative dose 
divided by 6. 
 
[IP_ADDRESS] Exposure for proposed doses relative to IL-6 binding 
In the planned study, median trough serum Ziltivekimab concentrations for the 6th dose of 
723, 1446, and 2892 ng/mL are expected to be attained with the proposed 7.5, 15, and 30 mg 
q4w doses, respectively.  Those concentrations are sufficient to ensure >99% of plasma IL-6 
would be bound (i.e., <1% free IL-6).  It is reasonable to expect that this magnitude of IL-6 binding would be associated with perturbation of inflammatory processes. 
[IP_ADDRESS] Exposures for proposed doses relative to the exposures at NOAEL dose in the 
toxicology study 
COR-001-02 will utilize SC doses of 7.5, 15, and 30 mg administered q4w for a total of 6 
months.  Based on the clinical PK for Ziltiv ekimab described above, exposures for the 
planned doses were estimated.  Those exposures we re then compared to those attained in a 
26-week Good Laboratory Practice (GLP)-compliant toxicology study in cynomolgus 
monkeys (Study 20134998) to determine the safety factors for the planned clinical study doses. 
For these planned doses, safety factors relative to the exposures at the NOAEL SC dose in 
the 26-week monkey study are at least 76-fold for the C
max after the 6th dose, and at least 118-
fold for the cumulative AUC 0-‚àû for the 6 doses. 
[IP_ADDRESS] Exposures for proposed doses relative to the exposures associated with clinically 
meaningful PD changes in prior clinical studies 
In the prior clinical studies, hs-CRP has been found to be a sensitive response to Ziltivekimab exposure, with clinically meaningful decreases ev en at the lowest doses tested.  Decreases 
were attained soon after the first dose, a nd the decreases were more prolonged as the 
Ziltivekimab dose is increased. Therefore, it is reasonable to expect that clinically   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
51 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296848] that the concept of inflammatory risk in renal patients has been in the public 
domain for decades, with an active basic res earch and clinical investigational community 
focused on its remediation, no therapy has been sp ecifically designed or developed to address 
it.  The advancement of an anti-inflammatory  therapy for CKD patients should offer the 
benefit of myocardial protection and potential tr eatment of heart failure in this otherwise 
vulnerable population. 
As for the risks associated with administra tion of Ziltivekimab, nonclinical toxicology 
studies established the NOAEL by [CONTACT_244122] (see the Ziltivekimab IB).  
Both in terms of local and systemic effects, Ziltivekimab was well tolerated, with no apparent 
adverse findings.  Of note, the highest Ziltivekimab dose planned for study allows an over 20-fold margin to NOAEL in the non-clinical toxicology program.  
Available data for anti-IL6R (tocilizumab) and anti-IL6 (siltuximab) therapi[INVESTIGATOR_244074]-[ADDRESS_296849] acceptable safety and tolerability profiles for the indications 
studied.  Injection-related and life-threatening hy persensitivity reactions are rare with these 
agents.  Anti-inflammatory therapi[INVESTIGATOR_244075], sometim es serious in nature.  Although anti-IL-6 
therapi[INVESTIGATOR_244076], their rates of infectious 
complications appear to be similar to ot her immune-modulatory biologic agents when 
accounting for patient-specific factors ( Sakai 2015 , [COMPANY_011] 2016 ).  Gastrointestinal 
perforation has been associated with anti -IL-6 therapy, however data suggests proper 
exclusion criteria may mitigate these risks ( Tanaka 2014 ). 
On balance then, the Sponsor proposes the poten tial risks to patients in this study are 
justifiable and the benefit-to-risk ratio positive.  Patients will be consented as to the potential 
risks and will be required to sign an ICF doc umenting their understanding of these risks and 
willingness to participate in the study.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
52 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 53 of 142 4 SELECTION OF STUDY POPULATION AND CRITERIA FOR 
WITHDRAWAL 
4.1 Inclusion Criteria 
After signing an informed consent form approved by [CONTACT_737]‚Äôs Institutional 
Review Board (IRB) or Independent Ethics Committee (IEC) to be eligible, potential study patients must meet all of the following criteria: 
1) Age ‚â•18 years at the time of signing of the Informed Consent Form (ICF). 
2) Stage 3-5 NDD-CKD, i.e. estimated glomerular filtration rate (eGFR) >10 and <60 
mL/min/1.73 m
2 using the CKD-EPI [INVESTIGATOR_91258] ( www.kidney.org/content/ckd-
epi-creatinine-equation-2009 ).  
3) Serum hs-CRP level t2.0 mg/L measured during the Screening Period. (Note: C-reactive 
protein may not be commonly measured in pa tients with CKD. Targeting patients with a 
history of advanced stage CKD, ASCVD, anem ia, metabolic syndrome, diabetic retinopathy 
and diabetes for screening will help increase the chances of identifying patients with CRP ‚â•2.0) 
4) The patient agrees to comply with the cont raception and reproduction restrictions of the 
study ( Appendix G ): 
a) Women of childbearing potential must be using a method of contraception, that is 
‚Äúhighly effective‚Äù (i.e., <1% failure rate) for at least [ADDRESS_296850] dose 
of study drug; 
b) Postmenopausal women must have had no me nstrual bleeding for at least [ADDRESS_296851] an elevated plasma 
follicle-stimulating hormone (FSH) level (i.e., >40 mIU/mL) at Screening; 
c) Women of childbearing potential must have a documented negative pregnancy test result at Screening. Patients with elevated Œ≤-HCG levels believed to be due to end-
stage renal disease may be enrolled if documented to not be pregnant; 
AND 
All male patients, from the day of dosing until  the final study visit, unless surgically 
sterile, must be willing to use a condom with  a partner (male patients with partners of 
childbearing potential must be willing to us e 2 effective methods of birth control, 1 
should be condom with spermicide) to preven t pregnancy and drug exposure of a partner, 
and refrain from donating sperm or fathering a child.   
4.2 Exclusion Criteria   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
53 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 54 of 142 Participants are excluded from the study if any of the following criteria apply: 
Laboratory Values 
1. Absolute neutrophil count <2.0 x 109/L during screening. 
2. Platelet count <120 x 109/L during screening. 
3. Spot urine protein to creatinine ratio >4000 mg/g, or 4.0 g/g. 
4. Alanine aminotransferase (ALT) or aspa rtate aminotransferase (AST) >2.5x ULN 
during screening. 
5. Positive testing for tuberculosis (TB) during screening. Blood testing 
(e.g., QuantiFERON) is preferred but a purified protein derivative ([COMPANY_003]) skin test 
read within 48-72 hours by a qualified healthcare professional may also be 
performed. If a patient is [COMPANY_003] positive but  QuantiFERON negative the patient is 
eligible.  
6. Evidence of human immunodeficiency virus-1 (HIV-1) or HIV-2 infection by [CONTACT_244123]. 
7. Hepatitis B or C by [CONTACT_44898] (e.g. hepati tis B surface antigen or hepatitis C antibody 
positive) measured during screening. 
Medical Conditions or Diseases 
8. Expected to require blood transfusion within 12-weeks post-randomization. 
9. Thromboembolic event within 12-weeks prior to randomization. 
10. Clinical evidence or suspi[INVESTIGATOR_244065]. 
11. History of peptic ulcer disease or gastroint estinal ulceration in the 12-months prior to 
randomization. 
12. History of active diverticulitis in the 12-months prior to randomization. 
13. History of inflammatory bowel disease that has been clinically active during the 12-months prior to randomization. 
14. Uncontrolled hypertension (defined as an average SBP >160 mmHg or an average diastolic blood pressure (DBP) >100 mmHg duri ng screening.  Patients may be re-
evaluated within 2 weeks, at the discretion of the investigator for this criterion if anti-hypertensive therapy has been  started or increased as a result of initial screening 
blood pressure being above these limits. 
15. Planned coronary revascularization (PCI or CABG) or any other major surgical procedure.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
54 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296852] 6 months prior to Randomization. 
17. History of [LOCATION_001] Heart Association Class IV congestive heart failure within 12-
weeks prior to randomization. 
18. Actively treated or active malignancy during the 1-year prior to randomization with the exception of successfully treated non metastatic basal cell or squamous cell 
carcinomas of the skin and/or local carcinoma in situ of the cervix. 
19. History of bone marrow or solid organ transp lant or anticipated to receive an organ 
transplant during the time frame of the study. 
20. Known allergy to the study drug or any of its ingredients. 
Prior or Current Medications 
21. Received any investigational drug within 30-days prior to screening visit. 
22. Received a live vaccine product within 14 da ys of study drug administration (Day 1) 
or expect to receive live vaccine during the Treatment Period (receiving a live 
vaccine within 14 days prior to enrollment is allowed). 
23. Treatment with a hypoxia-inducible factor (HIF) stabilizer (e.g., molidustat, roxadustat) or an erythropoietin-mimetic, e.g., erythropoietin alpha or beta, darbopoietin alpha, or continuous erythropoiesis receptor activator (CERA), within 
6-weeks prior to randomization or during treatment period. 
24. Expected to receive any investigational drug or any of the exclusionary drugs listed in 
Section 15.1 during the Treatment Period or Safety Follow-Up Period. 
25. Chronic use of systemic immunosuppressive drugs during the screening period or 
anticipated use of such drugs any time during the study. Note: Use of otic, ophthalmic, inhaled, and topi[INVESTIGATOR_244077]. Oral prednisone up to 5 mg per day is (or equivalent) is permitted if 
dose has been stable for at least 4 weeks prior to screening, and no dose changes are 
planned during study participation. 
26. Use of systemic antibiotics, systemic antivirals, or systemic antifungals during the screening period (‚ÄúSystemic‚Äù is defined as oral or intravenous drugs that are absorbed into the circulation). 
27. Requiring an indwelling catheter of any type. 
General Exclusions 
28. Currently breastfeeding.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
55 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296853] of the study or interpretation of the study results, or that would in 
the opi[INVESTIGATOR_244078].  
 
4.3 Criteria for Discontinuation of Study Drug  
It may be necessary for a participant to perm anently discontinue study intervention. If study 
intervention is permanently discontinued, the pa rticipant shall remain in the study to be 
evaluated on all early termination and safety follow-up procedures per the Schedule of 
Assessments (SOA) in Section 5.3.9  and Section 5.6 . Study drug may be prematurely 
discontinued for a number of reasons, including: 
x An intercurrent illness at the discretion of the investigator; 
x Any intolerable AE that cannot be ameliorated  by [CONTACT_244124][INVESTIGATOR_244079]; 
x In the event of severe injection related reac tions,  anaphylaxis, or hypersensitivity 
(Section 8.2  and Section 4.5 ); 
x If at any point during the study, >10% of subjects enrolled experience anaphylaxis, 
additional enrollment will stop in the stud y, and all patients in the study will 
discontinue receiving study drug ( Section 8.2 and Section 4.4 ); 
x Pregnancy; 
x Organ transplantation or development of another indication for chronic 
immunosuppression; 
Reasons for all withdrawals/discontinuations of Study Drug will be recorded, and the Medical Monitor should be informed of all such cases as they occur. Temporary discontinuation of study intervention and restarts may be performed per Section 4.5 . 
4.4 Anaphylaxis Study Stoppi[INVESTIGATOR_244080] ‚â•10% of participants experience an anaphylaxis event, the 
anaphylaxis study stoppi[INVESTIGATOR_244081]. The study stoppi[INVESTIGATOR_244082]. Additionally, all randomized participants currently receiving study drug will immediately discontinue further study drug administration. The remaining study procedures and visits may be performed if deemed necessary by [CONTACT_1034].   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
56 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296854] their study drug administration temporarily suspended during the 
course of the study. Study drug administration should be temporarily withheld if the participant experiences one or more of the following: 
x ALT >3x ULN (moderate)  
x Neutrophils <1000/mm
3 (severe) 
x Platelet count <50,000/mm3 (severe) 
x Platelet count <75,000/mm3 (moderate) with evidence of concurrent TIMI major 
bleeding.  
Laboratory measures should be present on two independent assessments.  After a temporary suspension of study drug has been performed, study drug may be restarted provided the participant has met the following criteria: 
x Neutrophils ‚â•1500/mm
3, and 
x Platelets ‚â•100,000/mm3 
No ongoing clinical sequalae attributable to neutropenia or thrombocytopenia, respectively. 
If, after restarting study drug, the event causing temporary discontinuation reoccurs study drug should be discontinued permanently.  
4.6 Participant Discontinuation/Withdrawal from the Study 
The following are descriptions of participant discontinuation and withdrawal from the study.  
This is not an exhaustive list , and each instance should be evaluated on a case-by-case basis. 
x Withdrawal of consent. A participant may elect to withdraw consent to treatment at 
any time. 
x Participants withdrawing their consent for all study procedures must be given the option to continue to give consent for passive follow-up (i.e., by [CONTACT_244125]) for AEs. 
x Participants discontinuing study drug treatment after receiving any amount of study 
drug should undergo all early termination and safety follow-up study procedures per 
the SOA ( Section 5.3.9  and Section 5.6 ) unless the participant also explicitly 
withdraws consent for these procedures as mentioned above.  The study drug has a 
long pharmacodynamic effect. Therefore, continued monitoring for pharmacodynamic effects and safety is prudent.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
57 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 58 of 142 x A participant may be withdrawn at any time at the discretion of the investigator for 
safety, behavioral, compliance, or administrative reasons. Participation in the early 
termination and safety follow-up procedures  will be evaluated on a case-by-case 
basis.  If possible, participants should take  part in the early termination and safety 
follow-up procedures in the SOA (Section 5.3.9  and Section 5.6 ). 
x If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any data collected before such a withdrawal of 
consent. 
x If a participant withdraws from the study, the participant may request destruction of 
any samples taken and not tested.  The investigator must document this in the site 
study records. 
4.[ADDRESS_296855] be taken if a par ticipant fails to return for any required study 
visit: 
x The site must attempt to contact [CONTACT_14315].  If possible, the site should attempt to reschedule the missed visit 
within any allowed visit or treatment window. 
o The site should advise the participant that it  is important to adhere to the assigned 
visit schedule. 
o The site shall attempt to ascertain whether or not the participant wishes to and/or 
should continue in the study. 
x Prior to a participant being deemed lost-to-follow-up, the investigator or designee must make every effort to regain contact [CONTACT_6635].  All attempts to regain contact [CONTACT_244126]‚Äôs medical record.  
If the participant continues to be unreachable, the participant will be 
considered to have withdrawn from the study. 
4.8 Study Completion 
Primary study completion is defined as the co mpletion of the Week 24 visit, even if one or 
more interim visits or procedures was/were missed. 
Completion of the Safety Follow-Up is defined by [CONTACT_244127] 32 visit even 
if one or more interim visits or procedures was/were missed.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
58 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 59 of 142 5 ENROLLMENT AND STUDY PROCEDURES 
Table 2  presents the procedures and assessments at each of the scheduled visits. Details of 
each visit are provided in Section 5.1  through Section 5.6 .   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
59 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 60 of 142 Table  2 SCHEDULE OF PROCEDURES 
 Screening1 Treatment Period Safety F/Up 
Visit Number -2 -1 1 2 3 4 5 6 N/A 7 8 9 10 11/ET 12 13/ET 
Visit Day Window -14 -7 1 8 22 29-35 43-49 57-63 78-84 85-91 113-119 141-147 155-161 162-168 190-196 218-224 
Visit Window  rr2  rr2 rr2            
Visit Week -2 -1 1 2 4 5 7 9 12 13 17 21 23 24/ET 28 32/ET 
ICF signed X                
Medical History/Update  X X              
Randomization   X              
Study drug administered (post-
assessments)   X   X  X  X X X     
Concomitant and Prior Medications  X X X X X X X  X X X X X X X 
Vital Signs2  X X  X X  X  X X X X X X X 
BMI   X       X    X   
Hematology3 X X X X X X X X  X X X X X X X 
Lipi[INVESTIGATOR_805] (fasting 8 hours)4  X X       X   X X X X 
Chemistry5 X X X X X X X X  X X X X X X X 
Spot urine protein-creatinine ratio  X        X       
Urinalysis (including albumin) [ADDRESS_296856] X                
Infectious Disease Screen8  X               
Special RBCs9   X       X    X X X 
Screening (total) IL-6 X                
IL-610   X  X X  X  X X X X X X X 
hs-CRP 11 X  X  X X  X  X X X X X X X 
Serum Pregnancy, FSH 12  X               
Ziltivekimab trough PK13   X X X X X X  X X X X X X X 
ADA14   X X X X X X  X X X X X X X 
12-lead ECG15  X            X   
CKD Biomarkers16  X X       X   X X   
NT-pro-BNP  X X       X   X X   
Lp(a), ApoB, ApoA1 (fasting 8 
hours)4  X X     X  X   X X     Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
60 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 61 of 142 Table  2 SCHEDULE OF PROCEDURES 
 Screening1 Treatment Period Safety F/Up 
Visit Number -2 -1 1 2 3 4 5 6 N/A 7 8 9 10 11/ET 12 13/ET 
Visit Day Window -14 -7 1 8 22 29-35 43-49 57-63 78-84 85-91 113-119 141-147 155-161 162-168 190-196 218-224 
Visit Window  rr2  rr2 rr2            
Visit Week -2 -1 1 2 4 5 7 9 12 13 17 21 23 24/ET 28 32/ET 
Lipid Profile by [CONTACT_105705] 
(fasting 8 hours)4   X       X   X X   
Cardiac Risk Biomarker17   X       X    X   
Storage samples for Exploratory 
Biomarkers and RNA Testing18  X        X    X   
DNA Testing (Stored Blood 
Samples)  X               
Limited Physical Examination19  X            X   
INR20   X X X X X X  X X X X X   
Adverse Events   X X X X X X  X X X X X X X 
PROMIS¬Æ 13a and Fatigue Items21   X   X    X   X X   
PROMIS¬Æ Sexual Interest Items21   X   X    X    X   
CARES (Corvidia ePRO)22  X   X    X    X X   
PGIS23  X   X    X     X   
PGIC24       X    X    X   
Optum SF-36 v2¬Æ25   X   X    X   X X   
EQ-5D-5L26   X   X    X    X   
ET = Early Termination; F/Up = Follow-up.  
 
1. If a Screening laboratory (excluding hematology) result is outsi de inclusion criteria parameters screening may be extended up t o one week to allow for 
retesting of lab test(s) that did not meet inclusion criteria. 
2. Vital signs include temperature, respi[INVESTIGATOR_2842], heart rate, and blood pressure (p atients may be re-evaluated within 2 weeks,  at the discretion of the PI 
[INVESTIGATOR_244083]-hypertensive therapy has been star ted or increased as a result of initial scre ening blood pressure).   Whenever possible , vital signs will be obtained 
after at least 5 minutes resting in the supi[INVESTIGATOR_244084], when necessary, in a semi-recumbent position. Vital signs will be d one prior to ECG recordings. 
3. Hematology:  hemoglobin, hematocrit, reticulocyte count, red bloo d count (RBC) indices (e.g., mean corpuscular volume (MCV), re d cell distribution 
width (RDW), platelets, white blood count (WBC), WBC differential.  
4. Lipi[INVESTIGATOR_244085] (fasting 8 hours): total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprote in (HDL), and 
triglycerides; Lp(a), ApoB, ApoA1.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
61 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 62 of 142 5. Chemistry: sodium, potassium, chloride, bicarbonate (or CO2), ca lcium, phosphate, alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), blood urea nitrogen (BUN) creatinine, total bilirubin, di rect bilirubin, alkaline phosphat ase, albumin, glucose and eGFR  calculated by 
[CONTACT_9289]-EPI [INVESTIGATOR_91258] ( https://www.kidney.org/content/ckd-epi-creatinine-equation-2009 ). 
6. At Weeks 1 and 24, a portion of urine will be stored frozen for future analysis. 
7. Iron Indices: TSAT, ferritin, iron, total iron binding capacity (TIBC). 
8. Infectious Disease Screen:  HIV [ADDRESS_296857] (e.g., QuantiFERON) is preferred, but a purified protein derivative ([COMPANY_003]) skin test read within 48-[ADDRESS_296858] comes back unable to perform analysis or indeterminate or confirmatory testing is required, the s creening window is 
extended until central laboratory results are available. ( https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm ). 
9. Special RBC: reticulocyte hemoglobin content (CHr). 
10. IL-6: Interleukin-6. Pre-dose sampling. 
11. hs-CRP: high-sensitivity C-reactive protein. Test can be repeated  once prior to randomization visit.  Results after screening w ill be blinded after the first 
dose. 
12. Pregnancy: E-hCG; FSH: Follicle Stimulating Hormone. 
13. On dosing Weeks 1, 5, 9, 13, 17, and 21, trough PK samples to  be collected within approximately -0.5 h pre-dose. Single PK bloo d samples will also 
be collected on Weeks 2, 4, 7, 23, 24/ET, 28, and 32/ET around the same time as the pre-dose samples were collected on previous  dosing visits. 
14. On dosing weeks 1, 5, 9, 13, 17, and 21, ADA: Anti-drug antibo dies specimens to be collected within approximately 0.[ADDRESS_296859] 12-lead ECG will be recorded in the supi[INVESTIGATOR_2547] (or with the patient as flat as possible) after vital signs assess ments.  The ECG will be 
locally read by [CONTACT_737]. 
16. Chronic Kidney Disease (CKD) Biomarkers: cystatin C and UACR. 
17. Cardiac Risk marker: SSA, fibrinogen and ST2. 
18. Exploratory storage samples will be two 5-ml tubes of plasma, tw o 5-ml tubes of serum, and two 5-mL tubes of whole blood (PBMC testing at 
Screening, Week 13 and Week 24). 
19. Limited physical exam to include skin, oropharynx, lungs, heart,  abdomen, extremities (including feet), and any areas suggested by [CONTACT_23805], with 
particular attention to signs of infection.  May be performed by  a physician-investigator or mid-level provider.  Record abnorm al findings in the source 
documents. 
20. INR performed by a local laboratory on Warfarin patients only. 
21. PROMIS ( Appendix B), to be done on subjects‚Äô  device at the clinic PRIOR to dosing. 
22. CARES Corvidia ePRO ( Appendix D) , [ADDRESS_296860]‚Äôs personal device; the questionnaire will be answered daily for 7 days prior 
to dose (Screening Day -7 to Day -1 prior to Dose 1 (Visit 1), Dose 2 (Visit 4), Dose  4 (Visit 7), and the last 2 weeks after D ose 6 (Visit 23-24). 
CARES: Daily recall 
(starts with Visit -1) = baseline averag e of the 7 consecutive assessments (Day -7 to Day -1) prior to Dose 1  
(starts with Visit 3) = end of month of Dose 1 
(no visit) = end of month of Dose 3  
(starts with Visit 10 and Visit 11)  = starts 2 weeks after Dose 6 
23. PGIS ( Appendix E ), to be done on subjects‚Äô device on the last day of CARES assessment.  
24. PGIC ( Appendix E ), to be done on subjects‚Äô device at the clinic PRIOR to dosing.  
25. Optum SF-36 v2¬Æ Health Survey (Appendix C ), to be done on subjects‚Äô device at the clinic PRIOR to dosing.  
26. EQ-5D-5L (Appendix F) , to be done on subjects‚Äô device  at the clinic PRIOR to dosing.  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
62 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 63 of 142 After signing the ICF, patients should be registered into the electronic data capture system to 
obtain a patient identification number for the study. 
5.1 Screening Visit Procedures (Up to 2 weeks, Days -14 to -7) ‚Äì Initial 
Screening 
Screening will be conducted in a stepwise manner. If a Screening laboratory result is outside 
inclusion criteria parameters screening may be extended up to one week to allow for retesting of lab test(s) that did not meet inclusion criteria.
   
Prior to conducting any study procedures informed consent will be obtained from the patient by [CONTACT_093] (or other study staff who are conducting the informed consent interview).  
The Initial Screening procedures will be conducte d after informed consent has been obtained. 
The following will be performed according to Table 2 . 
x ICF signed 
x Hematology 
x Chemistry 
x Iron Indices 
x TMPRSS6 Genotype  
x hs-CRP (may be repeated once up to randomization) 
x Screening IL-6 (total) 
 
5.2 Screening Visit Procedures (Week -1; Days -7 to -1) ‚Äì Full Screening  
Every effort should be made to obtain the blood tests for each visit on the same day of the 
week (e.g. on Wednesdays).  
The following list summarizes the procedures for Week -1.  Please see Table 2 for full 
details . 
x Medical History 
x Concomitant and Prior Medications 
x Vital Signs  
x Hematology 
x Lipi[INVESTIGATOR_805] (fasting 8 hours) 
x Chemistry    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
63 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 64 of 142 x Spot urine protein-creatinine ratio  
x Infectious Disease Screen (If the test comes back unable to perform analysis or 
indeterminate or confirmatory testing is required, the screening window is extended 
until central laboratory results are available) 
x Serum Pregnancy, FSH  
x 12-lead ECG  
x CKD Biomarkers  
x NT-pro-BNP 
x Lp(a), ApoB, ApoA1 (fasting 8 hours) 
x Storage samples for Exploratory Bioma rkers and RNA Testing (PBMC testing)  
x DNA Testing ‚Äì Stored Blood Samples  
x Limited Physical Examination 
x CARES Corvidia ePRO 
x PGIS 
The following sections summarize the procedures for the Treatment Period. Please see Table 
2 for full details .  
5.3 Treatment Period (Study Weeks 1 - 21) 
Important: Study Visits during which Study Drug injections are required should be planned for the same day of the week so that Study Drug administration can occur on a schedule of every 28 days.  See Section 6.1.1  for guidance on missed doses. 
5.3.1 Visit 1, Week 1, Day 1 (Pre-Dose) 
x Medical History (update if necessary) 
x Randomization (may occur on Day -1 if needed) 
x Concomitant and Prior Medications 
x Vital Signs 
x BMI 
x Hematology 
x Lipi[INVESTIGATOR_805] (fasting 8 hours)   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
64 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 65 of 142 x Chemistry 
x Urinalysis (including albumin); portion stored frozen 
x Iron indices  
x Serum hepcidin  
x Special RBCs 
x IL-6 (pre-dose) 
x hs-CRP 
x Ziltivekimab trough PK 
x ADA (pre-dose) 
x CKD Biomarkers 
x NT-pro-BNP 
x Lp(a), ApoB, ApoA1 (fasting 8 hours) 
x Lipid profile by [CONTACT_105705] (fasting 8 hours) 
x Cardiac Biomarkers: SSA, fibrinogen and ST2 
x Coagulation (INR): Patients on warfarin only 
x Adverse Events 
x PROMIS¬Æ 13a and Fatigue Items 
x PROMIS¬Æ Sexual Interest Items 
x Optum SF-36 v2¬Æ Health Survey 
x EQ-5D-5L  
 
5.3.2 Visit 1, Week 1, Day 1 (Dosing/Post-Dose) 
Administration of the first dose of Study Drug will continue to define Study Day 1. 
Prepare the Study Drug prior to the anticipated time of administration (see Section 6.1.1  and 
Pharmacy Manual). 
x Study Drug (after all assessments) 
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
65 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 66 of 142 5.3.3 Visit 2, Week 2, Day 8 
x Concomitant and Prior Medications 
x Hematology 
x Chemistry 
x Ziltivekimab trough PK 
x ADA 
x Coagulation (INR): Patients on warfarin only 
x Adverse Events 
 
5.3.4 Visit 3, Week 4, Day 22 
x Concomitant and Prior Medications 
x Vital Signs 
x Hematology 
x Chemistry 
x IL-6 
x hs-CRP 
x Ziltivekimab trough PK 
x ADA (pre-dose) 
x Coagulation (INR): Patients on warfarin only 
x Adverse Events 
x CARES Corvidia ePRO 
x PGIS 
 
5.3.5 Visit 4, Week 5 
x Study drug administered (after all assessments) 
x Concomitant and Prior Medications 
x Vital Signs   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
66 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 67 of 142 x Hematology 
x Chemistry 
x IL-6 (pre-dose) 
x hs-CRP 
x Ziltivekimab trough PK 
x ADA (pre-dose) 
x Coagulation (INR): Patients on warfarin only 
x Adverse events 
x PROMIS¬Æ 13a and Fatigue Items 
x PROMIS¬Æ Sexual Interest Items 
x PGIC 
x Optum SF-36 v2¬Æ Health Survey 
x EQ-5D-5L  
 
5.3.6 Visit 5, Week 7 
x Concomitant and Prior Medications 
x Hematology 
x Chemistry 
x Ziltivekimab trough PK 
x ADA 
x Coagulation (INR): Patients on warfarin only 
x Adverse Events 
 
5.3.7 Visits 6 through 9, Weeks 9 through 21 
x Concomitant and Prior Medications (not Week 12) 
x Vital Signs (not Week 12) 
x BMI (Week 13 only)   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
67 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 68 of 142 x Hematology (not Week 12) 
x Lipi[INVESTIGATOR_805] (fasting 8 hours; Week 13 only) 
x Chemistry (not Week 12) 
x Spot urine protein-creatinine ratio (Week 13 only) 
x Urinalysis (including albumin) (Week 13 only) 
x Iron Indices (Week 13 only) 
x Serum hepcidin (Week 13 only) 
x Special RBCs (Week 13 only) 
x IL-6 (pre-dose) (not Week 12) 
x hs-CRP (not Week 12) 
x Ziltivekimab trough PK (not Week 12) 
x ADA (pre-dose) (not Week 12) 
x CKD Biomarkers (Week 13 only) 
x NT-pro-BNP (Week 13 only) 
x Lp(a), ApoB, ApoA1 (fasting 8 hours; Weeks 9 and 13 only) 
x Lipid profile by [CONTACT_105705] (fasting 8 hours; Week 13 only) 
x Cardiac Risk Biomarkers: SSA, fibrinogen and ST2 (Week 13 only) 
x Storage samples for Exploratory Bioma rkers and RNA Testing (Week 13 only) 
x Coagulation (INR): Patients on warfarin only (not Week 12) 
x Adverse Events (not Week 12) 
x PROMIS¬Æ 13a and Fatigue Items (Week 13 only) 
x PROMIS¬Æ Sexual Interest Items (Week 13 only) 
x CARES Corvidia ePRO (Week 12 only) 
x PGIS (Week 12 only) 
x PGIC (Week 13 only) 
x EQ-5D-5L  (Week 13 only) 
x Optum SF-36 v2 (Week 13 only)   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
68 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 69 of 142  
5.3.8 Visits 6 through 9, Weeks 9 through Week 21 (Dosing/Post-Dose) 
x Study Drug (after all assessments) (not Week 12) 
 
5.3.9 Visit 10, Week 23 and Visit 11, Week 24/ET 
x Concomitant and Prior Medications 
x Vital Signs 
x BMI (Week 24 only) 
x Hematology 
x Lipi[INVESTIGATOR_805] (fasting 8 hours) 
x Chemistry 
x Urinalysis (including albumin); portion stored frozen at Week 24 only 
x Iron Indices  
x Serum hepcidin (Week 24 only) 
x Special RBCs (Week 24 only) 
x IL-6 
x hs-CRP 
x Ziltivekimab trough PK 
x ADA  
x 12-lead ECG (Week 24 only) 
x CKD Biomarkers 
x NT-pro-BNP 
x Lp(a), ApoB, ApoA1 (fasting 8 hours) 
x Lipid profile by [CONTACT_105705] (fasting 8 hours) 
x Cardiac Biomarker: SSA, fibrinogen and ST2 (Week 24 only) 
x Storage samples for Exploratory Biomarkers and RNA Testing (Week 24 only) 
x Limited Physical Examination (Week 24 only)   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
69 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 70 of 142 x Coagulation (INR): Patients on warfarin only 
x Adverse Events 
x PROMIS¬Æ 13a and Fatigue Items 
x PROMIS¬Æ Sexual Interest Items (Week 24 only) 
x CARES (Corvidia ePRO) [2 weeks after Week 21 (Dose 6) for 14 consecutive days] 
x PGIS (Week 24 only) 
x PGIC (Week 24 only) 
x Optum SF-36 v2¬Æ 
x EQ-5D-5L (Week 24 only) 
 
5.4 Safety Follow-Up Visits 12 and 13 Procedures (Study Weeks 28 and 32) 
x Concomitant and Prior Medications 
x Vital Signs 
x Hematology 
x Lipi[INVESTIGATOR_805] (fasting 8 hours) 
x Chemistry 
x Iron Indices  
x Special RBCs 
x IL-6 
x hs-CRP 
x Ziltivekimab trough PK  
x ADA  
x Adverse Events 
 5.5 Unscheduled Visit 
Additional clinical visits ma y be scheduled at the In vestigators‚Äô discretion in order to follow  
or evaluate AEs.  The reason for a given unscheduled visit will be recorded.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
70 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296861] be performed at any unscheduled visit occurring prior to Week 32: 
x Record adverse events 
x Record any medication changes. 
5.6 Early Termination Visit 
There are two possible types of Early Termination visits: 
Early Termination Visit 1 (ET-1) : Randomized patients terminating from the study 
prematurely prior to Study Week 24 should underg o an Early Termination Visit during which 
Week 24 procedures are performed. 
Early Termination Visit 2 (ET-2) : Randomized patients terminating from the study 
prematurely after Study Week 24 visit, but before Week 32 should undergo an early 
termination visit during which Week  32 procedures are performed. 
Criteria for discontinuation of Study Drug can be found in Section 4.3.  
Patients may be withdrawn from the study for a number of reasons, including those outlined 
below: 
x Patients withdrawing their consent for all st udy procedures.  Patients must be given 
the option to continue to give consent for passive follow-up (i.e. by [CONTACT_244125]) for adverse events through Study Week 21. 
x Discontinuation of the study by [CONTACT_1034].   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
71 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 72 of 142 6 DRUG SUPPLIES AND DOSING 
6.1.1 Dosing and Administration 
The dose of Ziltivekimab for subcutaneous (SC) injection must be prepared using aseptic 
techniques.  Drug Product is presented as a single use vial and any unused portion must be discarded. 
Ziltivekimab is supplied as a liquid for injection.   The rationale for the planned doses in the study is described in Section 3.5.4. D etails on the 
dosing and administration are provided in Table [ADDRESS_296862] an appropriate background 
(i.e., physician, pharmacist, pharmacy technicia n, nurse, or other personnel approved by [CONTACT_429]) and has been appropriately trained.  P lease see Pharmacy Manual for full details. 
The final required volume of Ziltivekimab is provided in Table 3. Please see the Pharmacy Manual for instructi ons on preparing and administering the Study 
Drug and storage of prepared Study Drug. Special Situations 
Patients who miss a dose of Study Drug may re ceive the missed Study Drug up to 15 days 
later. 
If the missed dose cannot be administered wi thin this time frame, the dose should be 
considered ‚Äúmissed‚Äù and the next dose admini stered at the next study visit as planned.  
In the above special situations, please ensure that blood testing and PK sampling that is timed 
with the administered dose must be adhered to. 
 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
72 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 73 of 142 Table 3 Planned Ziltivekimab Doses and Administered Volumes 
 Dose Cohort 1 Dose Cohort 2 Dose Cohort 3 Dose Cohort 4 
Intervention 
Name [CONTACT_244163] 7.5 mg 15 mg 30 mg N/A 
Dose 
Administration 7.5 mg in 1 mL 
injection  15 mg in 1 mL 
injection 30 mg in 1 mL 
injection  1 mL PBO 
injections \ 
Route of 
Administration SC injections SC injections SC injections SC injections 
Frequency Every 28 days per 
SOA Every 28 days per 
SOA Every 28 days per 
SOA Every 28 days per 
SOA 
Abbreviations: PBO = placebo; SC = subc utaneous; SOA = schedule of activities 
 
The date and time of administration of Study Dr ug must be recorded in the appropriate 
sections of the CRFs. 
6.1.[ADDRESS_296863] be stored at 2 to  8 ¬∞C in the original container and must not 
be frozen. 
6.1.3 Formulation and Packaging 
Table 4 Composition for Ziltivekimab for Injection, Amount per mL (7.5 
mg/Vial, 15 mg/Vial, 30 mg/Vial, and Placebo) 
Component Amount per mL 
(7.5 mg vial) Amount per mL 
(15 mg vial) Amount per mL 
(30 mg vial) Amount per mL 
(Placebo vial) 
Ziltivekimab 7.5 mg 15 mg 30 mg 0 mg 
Trehalose dihydrate 50.00 mg 50.00 mg 50.00 mg 50.00 mg 
L-Arginine 
monohydrochloride 14.75 mg 14.75 mg 14.75 mg 14.75 mg 
L-Methionine 1.49 mg 1.49 mg 1.49 mg 1.49 mg 
L-Histidine 1.55 mg 1.55 mg 1.55 mg 1.55 mg 
L-Histidine mono-
hydrochloride monohydrate 2.10 mg 2.10 mg 2.10 mg 2.10 mg 
Polysorbate 80 0.70 mg 0.70 mg 0.70 mg 0.70 mg 
Water for Injection q.s. to 1.0 mL q.s. to 1.0 mL q.s. to 1.0 mL q.s. to 1.0 mL 
Abbreviations:  q.s. = quantum satis     Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
73 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296864] or designated qualified  individual will write the date dispensed, 
dose dispensed, and the patient ‚Äôs identification number, and initials on the Drug 
Accountability Source Documents.  All medicat ion supplied will be accounted for on the 
Drug Accountability Record.  All partially used  or unused drug supplies will be destroyed at 
the site in accordance with approved written  site procedures or returned to Corvidia 
Therapeutics.  The Investigator will maintain a record of the amount and dates when unused 
supplies were either destroyed or returned to Corvidia Therapeutics.  All records will be 
retained as noted in Section 13.5 .   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
74 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 75 of 142 7 PRIOR AND CONCOMITANT MEDICATIONS AND TREATMENTS 
7.1 Prior Medications and Treatments 
See Section 4.1 and Section 4.2  for restrictions on prior medications and treatments. 
7.2 Concomitant Medications and Treatments 
Patients with cardiovascular disease should be  treated according to published guidelines 
throughout the trial; in addition, patients may receive concomitant medications as clinically 
indicated with the following restrictions: 
Systemic immunosuppressive drugs (i.e., such as cyclosporine, tacrolimus, sirolimus, 
mycophenolate, oral and intravenous glucocortic oids other than prednisone [or equivalent] 
up to a dose of 5 mg per day) may not be presc ribed at any time during Study.  Topi[INVESTIGATOR_44785] 
(e.g., cyclosporine eye drops) is not restricted 
Note: Use of otic, ophthalmic, inhaled, and topi[INVESTIGATOR_244086].  Short-term systemic glucocorticoid use (e.g., less than 5 consecutive days) for managing acute illnesses is also not restricted. 
Narrow therapeutic window medications that are influenced by [CONTACT_244128] 
(See list in Appendix A) may not be prescribed at any time during Study.  
x Warfarin is permitted, but the INR must be monitored closely and, at minimum, 
according to the protocol Schedule of Events (see Table 2).  
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
75 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296865]. 
For the purposes of this study, a hypersensitivi ty reaction is defined as an acute onset of an 
illness with involvement of the skin, mucosal tissue, or both during injection of the Study 
Drug (but does not meet the definition of anaphylaxis described above). 
If signs and symptoms of injection -related reactions are observed and the patient‚Äôs 
cardiovascular status is stable:  
x If the patient continues to show signs a nd symptoms of hypersensitivity, administer 
an SC dose of antihistamine, if the Invest igator believes this is appropriate.   
x In patients who have experienced mild or moderate injection reactions during prior 
Study Drug administrations, antihistamines and/or acetaminophen may be 
administered prophylactically prior to subse quent injections, at the discretion of the 
Investigator. 
x In patients who experience severe inje ction-related reactions, anaphylaxis, or 
hypersensitivity (see definition and grading below): 
x Permanently discontinue the Study Drug 
x Treat the patients as for an anaphyla ctic reaction with IV antihistamines, 
corticosteroids, epi[INVESTIGATOR_238], inhaled bronchodilators, and other measures as necessary  
x Obtain a blood sample for the presence of anti-drug antibodies 
The patient should remain in the study for continued follow-up, but should receive no further Study Drug. 
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
76 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296866] medical occurrence that occurs to a 
participant during the course of a study, or the protocol-defined time after study termination, 
whether or not that event is considered Study Drug-related. 
Examples include:  
x Any treatment emergent signs and symptoms  (events that are marked by a change 
from the patient‚Äôs baseline/entry status [e.g., an increase in severity or frequency of 
pre-existing abnormality or disorder]);  
x All reactions from Study Drug, abuse of dru g, withdrawal phenomena, sensitivity or 
toxicity to Study Drug; 
x Apparently unrelated illnesses; 
x Injuries or accidents (e.g., for a fall second ary to dizziness, record ‚Äúdizziness‚Äù as the 
event and include the information about the fall in the comment/narrative section and 
information about any inj ury secondary to the fall as part of the ‚Äúoutcome‚Äù) ; 
x Exacerbations (increase in frequency or severity) of symptomatology, subjective 
patient-reported events, new clinically signif icant abnormalities in clinical laboratory, 
physiological testing or physical examination; 
x Abnormal laboratory findings considered by [CONTACT_210699].  In general, an abnormal la boratory value should not be recorded as an 
adverse event unless: 
o It is associated with clinical signs or symptoms,  
o Requires an intervention, results in a serious adverse event, or  
o Results in study termination or inte rruption/discontinuation of study 
treatment.  
However, if none of the above a pplies, but the laboratory abnormality is considered clinically 
significantly worsened, it should be reported as a laboratory AE (e.g., ‚Äúincreased white blood 
cell count‚Äù) .  When recording an adverse event resu lting from a laboratory abnormality, the 
resulting medical condition rather than the a bnormality itself should be recorded (e.g., record 
‚Äúanemia‚Äù rather than ‚Äúlow he moglobin‚Äù).    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
77 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 78 of 142 9.2 Serious Adverse Event Definition 
An SAE is any AE, occurring at any dose and regardless of causality, that: 
x Results in death; 
x Is life-threatening.  Life-threatening means that in the opi[INVESTIGATOR_244087], the patient was at immediate risk of death from the reaction as it 
occurred, (i.e., it does not include a react ion that hypothetically might have caused 
death had it occurred in a more severe form); 
x Requires inpatient hospi[INVESTIGATOR_43242]. 
Hospi[INVESTIGATOR_6930]/or surgical operations scheduled to occur during the 
study period, but planned before the signing for the ICF, are not considered AEs if the 
illness or disease existed before the patient was enrolled in the trial, provided that it 
did not deteriorate in an unexpected manner during the trial (e.g., surgery performed 
earlier than planned); 
x Results in persistent or significant disability /incapacity.  Disability is defined as a 
substantial disruption of a person‚Äôs ability to conduct normal life functions;  
x Is a congenital anomaly/birth defect; 
x Is an important medical event.  An importan t medical event is an event that may not 
result in death, be life-threatening, or re quire hospi[INVESTIGATOR_244088], based upon appropriate medi cal judgment, it may jeopardize the 
patient and may require medical or surg ical intervention to prevent one of the 
outcomes listed in the definitions for SAEs.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
A distinction should be made bet ween the terms ‚Äúserious‚Äù and ‚Äúsevere‚Äù since they are not  
synonymous.  The term ‚Äúsevere‚Äù is often used to describe the intensity (severity) of a specific 
event (as in mild, moderate, or severe myocardi al infarction); the event itself, however, may 
be of relatively minor medical significance  (such as severe headache).  This is not the same 
as ‚Äúserious,‚Äù which is based on patient /event outcome or action criteria usually associated 
with events that pose a threat to a patient ‚Äôs life or functioning.  A severe adverse event does 
not necessarily need to be considered serious.  For example, persistent nausea of several 
hours duration may be considered severe nausea but not an SAE if the event does not meet the serious criteria.  On the other hand, a stroke  resulting in only a minor degree of disability 
may be considered mild, but would be define d as an SAE based on the above noted serious   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
78 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 79 of 142 criteria.  Seriousness (not severity) serves as a guide for defining regulatory reporting 
obligations. 
9.[ADDRESS_296867] be reported to the Sponsor within 
24 hours of the I nvestigator‚Äôs awareness, even if not meeting the definition of a serious 
adverse event: 
x Serious infections. 
x Severe injection-related reactions. 
x Gastrointestinal perforations. 
x Hypersensitivity reaction during study drug administration. 
x Anaphylaxis occurring at any time, even if considered unrelated to the study drug. A 
CRF for the collection of the details of such reactions will be available in the EDC. 
x Neutrophil <500/mm3 (severe), or neutrophil <1000/mm3 (severe) with evidence of 
concurrent infection. These events will be separately summarized by [CONTACT_244129]. 
x Thrombocytopenia (platelet count <50,000/mm3 (severe)) or platelet count 
<75,000/mm3 (moderate) with evidence of concurrent TIMI major bleeding. These 
events will be separately summarized by [CONTACT_244099]. 
x Malignancies 
x Description of additional safety assessments by [CONTACT_244099]: vital signs, 
ECG, clinical laboratory, and anti-drug antibodies (binding and neutralizing). 
9.4 Assessment of Causal Relationship 
The causal association of AEs to Study Drug administration should be determined as follows: 
The following categories should be used in the causality assessment of suspected adverse 
reactions:  
Probable  
The AE follows a reasonable temporal sequence f rom the time of Study Drug administration; 
and/or follows a known response pattern to the Study Drug; and was unlikely to have been 
produced by [CONTACT_244130] ‚Äôs clinical state, therapeutic intervention or 
concomitant therapy. 
Possible 
The AE follows a reasonable temporal sequence f rom the time of Study Drug administration; 
and/or follows a known response pattern to the Study Drug; but could have been produced by   [CONTACT_244131]-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
79 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 80 of 142 other factors such as the patient ‚Äôs clinical state, therapeutic intervention or concomitant 
therapy. 
Unlikely  
The AE does not follow a reasonable temporal  sequence from the time of Study Drug 
administration; and was most likely produce d by [CONTACT_244130] ‚Äôs clinical 
state, therapeutic intervention or concomitant therapy.  
Unrelated 
This category is applicable to those AEs that are judged to be clearly and incontrovertibly 
due only to extraneous causes (the patient‚Äôs clinical  state, therapeutic intervention or 
concomitant therapy) and do not meet the criteria for Study Drug relationship listed under Probable, Possible, or Unlikely.  
An AE with causal relationship not initially determined will require follow-up to assign causality.  
9.[ADDRESS_296868] determine the severity of the event or laboratory value according to 
Table 5  (refer to laboratory manual for guidance);  severity describes the intensity of the 
adverse event or lab value. 
Table 5 Severity Assessment for AE s and Abnormal Laboratory Values 
 
Mild  Awareness of sign or symptom, but easily tolerated; lab value mildly 
outside normal reference range but not clinically significant  
Mode rate Discomfort enough to cause interfer ence with normal daily activities; 
lab value moderately outside normal reference range and clinically 
significant  
Severe  Inability to perform normal daily activities; lab value severely outside 
normal reference rang e and clinically significant 
 
9.6 Adverse Event Reporting 
The AE reporting period starts with randomization and continues through the Week 32 study 
visit.  Patients in this study who experience a drug-related AE or SAE will be followed until the AE or SAE is resolved or stabilizes per the Investigator ‚Äôs judgment, even if this occurs 
after the final study visit.  All AEs spontaneously reported by [CONTACT_5363]/or in response to an open question from study personnel or revealed by [CONTACT_4171], physical examination, 
or other diagnostic procedures will be recorde d and reported on the appropriate CRF.  When   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
80 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 81 of 142 a unifying diagnosis has been made that accounts for several possible signs and/or symptoms, 
the unifying diagnosis should be selected as the AE term.  For example, the combination of general malaise, mild fever, headache, and rhin itis should be described as ‚Äúupper respi[INVESTIGATOR_244089]‚Äù if this diagnosis has been made, rather than reporting the individu al symptoms as 
separate events. 
If any laboratory test is newly abnormal during the treatment or safety follow-up period, it 
will be followed at the discretion of the Investigator.  Abnormalities of laboratory tests which are, in the opi[INVESTIGATOR_689], clinically significantly worse compared to baseline, or for which a medical intervention is initiated, should be reported as AEs on the AE CRF. 
9.[ADDRESS_296869] Information 
 
 
Telephone:  
Facsimile:  
e-mail:  
 
 
Hypersensitivity reactions (see Section 8.2 ) occurring during the Study Drug injection and 
anaphylaxis occurring anytime during Weeks 1 ‚Äì 21 of the study should be reported in the 
EDC as adverse or serious adverse events on the AE and SAE CRFs within 24 hours of the 
site‚Äôs awareness of the event .  Please submit as much information as is available with the 
initial report. 
Corvidia Therapeutics will immediately notify the Investigator about important safety or 
toxicology information as it becomes available.  It is the responsibility of the Investigator to promptly notify the IRB/ IEC about new and relevant safety information regarding the Study Drug, including serious adverse drug reactions involving risk to human subjects, in   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
81 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 82 of 142 accordance with the applicable policies.  An unexpected event is one that is not listed by 
[CONTACT_244132]‚Äôs Brochure . 
9.[ADDRESS_296870], in turn, also be notified by [CONTACT_244133] a Pregnancy Form and faxing or emailing it to  (see Section 9.7).  The pregnancy must be 
followed up through delivery or other fetal outcome.  For any abnormal fetal outcome, including congenital anomaly or birth defect, spontaneous or therapeutic abortion, still birth, 
pre-mature birth, or other outcome other than live normal birth, the Investigator should promptly report to the Sponsor the abnormal fetal outcome on an SAE form.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
82 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 83 of 142 10 STUDY ASSESSMENTS 
10.1 Pharmacodynamic Assessments 
10.1.1 CKD symptoms, Fatigue, and Health-Related Quality of Life  
CKD symptoms, fatigue, and health-related quality  of life will be assessed with the PROMIS 
Fatigue 13a short form and selected items from the PROMIS fatigue item bank ( Appendix 
B), Optum SF-36 v2¬Æ Health Survey PCS, MCS, and domain scores ( Appendix C ), 
PROMIS interest in sexual activity item ( Appendix B ), the Corvidia ePRO ( Appendix D ), the 
patient global impression of severity (PGIS) and the patient global impression of change 
(PGIC) (Appendix E),  and the EQ-5D-5L ( Appendix F ). 
10.1.[ADDRESS_296871]  measure of IL-6 function. Serum albumin is 
also closely negatively correlated with inflammation. Key hematologic and iron metabolism 
assessments include Chr, TSAT, TIBC, ferritin, serum iron, and hepcidin. 
Biomarkers of inflammation and cardiovascular  risk include serum SSA, fibrinogen, NT-pro-
BNP and ST2, which were chosen based on the documented detrimental effects of IL-6, and 
beneficial effects of anti-IL-6 therapi[INVESTIGATOR_014], on inflammation and on ca rdiac structure and 
function. 
Biomarkers for CKD will be evaluated including cystatin C, creatinine, and urine albumin-to-
creatinine ratio (UACR). 
10.2 Safety Assessments (other than Adverse Events) 
10.2.[ADDRESS_296872] 12-lead EC G will be recorded in the supi[INVESTIGATOR_2547] 
(or with the patient as flat as possible) after vital signs assessments.  The ECG will be locally 
read by [CONTACT_737].   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
83 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 84 of 142 10.2.3 Physical Examination 
Scheduled (limited) physical exams must include  at a minimum an examination of the skin, 
oropharynx, lungs, heart, abdomen, extremities (including feet), and any areas suggested by 
[CONTACT_23805], with particular attention to signs of infection. 
10.2.4 Clinical Laboratory Testing 
Details on the collection, processing, storage, and shipment of cent ral lab samples are 
contained in the Laboratory Manual.  Coagulati on: INR (only for patients on warfarin) will 
be performed at the Local Laboratory.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
84 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 85 of 142 11 STATISTICAL CONSIDERATIONS AND DATA ANALYSIS 
The study design and objectives are described in Sections 2.0 and 3.0, respectively. Details of 
all planned analyses are provided in the Statistical Analysis Plan (SAP).  
11.1 Sample Size 
The primary efficacy endpoint is percent change  from baseline in hs-CRP (average of the 
hs-CRP value prior to randomization and Day 1) to Week 13 between each active group and 
placebo. Based on the observed treatment difference in percent change from baseline in 
hs-CRP of -60.74% between combined COR-001-01 active groups and placebo and the 
associated pooled SD of 16.893% in hs-CRP at Week 4 from the final analysis of study 
COR-001-SC1, a sample size of 54 per group yi elds more than 99% power with 2-sided 
alpha=0.05. Taking into consideration the dropout rate of 10% by [CONTACT_2054], a sample size of 60 per group is planned for this study 
Approximately 240 patients (60 per group) will be randomized.  
11.2 Randomization 
Approximately 240 patients will be randomized 1:1:1:1 to Ziltivekimab Dose #1 (7.5 mg), 
Ziltivekimab Dose #2 (15 mg) or Ziltivekimab  Dose #3 (30 mg) or Placebo as they became 
eligible to proceed with dosing on Day 1. Patien t randomization will be stratified by [CONTACT_244134] ( ‚â•11 or <11 g/dL) and CKD stage (3, 4 or 5). Approximately 240 patients will 
be randomized 1:1:1:1 (60 per group) into the trial. 11.3 General Statistical Considerations and Definitions 
11.3.1 General Statistical Methods 
All study-collected data will be  summarized by [CONTACT_244135], using descriptive statistics, graphs, and/ or raw data listings.  Descriptive statistics 
for continuous variables will include number of patients (n), mean, standard deviation (SD), 
median, quartiles (Q1 and Q3), minimum (min) and maximum (max) values.  Analysis of 
categorical variables will include frequency and percentage. 
11.3.2 Analysis Populations 
Intent-to-Treat (ITT) analysis population: all patients randomized. 
The ITT analysis populations will be the pr imary population for the analyses of disposition 
and baseline data and efficacy endpoints. 
Per-Protocol analysis population : all patients randomized who completed the study and did 
not incur a significant protocol violation
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
85 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 86 of 142 For the ITT analysis populations and per-protoc ol populations, treatment classification will 
be based on the randomized treatment.   
Pharmacokinetics (PK) analysis population : all patients randomized and who received at 
least one dose of Test or Reference product an d who had at least one post-dose PK blood 
sample  
Safety analysis population : all patients randomized and who received at least one dose of 
Test or Reference product. For the PK analysis population and safety populat ion, treatment classification will be based 
on the treatment actually received.  
11.3.[ADDRESS_296873] will be used for the 
summary for that visit. 
The observational period for the study will s tart from informed consent and end with study 
completion (see Section 4.4  for the definition of study completion).  Any event occurring 
after the defined observational period, even if collected on the CRF, may not be included in 
the planned statistical analysis.  However, all data, including that reported after the defined 
observational period, will be included in the patient data listings .  
For evaluations that are collected at multiple occasions prior to initiation of Study Drug, the 
latest evaluation will be considered the "Basel ine" evaluation for analysis, unless otherwise 
specified. 
11.3.4 Missing Data Handling 
Unless otherwise specified, missing data will not be imputed and the analyses will be based 
on observed data only. 
11.4 Statistical Analyses 
11.4.1 Demographic and Background Characteristics 
Patient demographics and baseline characteris tics will be summariz ed by [CONTACT_244136], per-protocol, and safety populations 11.4.2 Study Drug and Concomitant Medications 
Summaries of prior (pre-base line) medications and conc omitant (baseline or later) 
medications will be provided by [CONTACT_68164]. Prior 
medications are defined as medications given before the first dose of study drug. 
Concomitant medications are defined as medicat ions taken before and continuing after first   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
86 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296874] dose of study drug. Medications will be coded with 
World Health Organization (WHO) Drug Dictionary .  Patients will be counted only once by 
[CONTACT_244137]. 
11.4.3 Efficacy Analysis 
For all efficacy variables, the number of patien ts (n), mean, standard deviation (SD), median, 
quartiles (Q1 and Q3), minimum (min) and maxim um (max) values for the observed value, 
change from baseline, or percent change from baseline (as applicable) will be reported. The 
difference (Ziltivekimab - Placebo) in changes or percent changes (as applicable) will be 
presented.  
A mixed model for repeated measures (MMRM) w ill be used to evaluate change or percent 
change from baseline. The model will in clude variables for baseline hemoglobin ( ‚â• 11 or < 
11 g/dL), CKD Stage (3, 4 or 5), treatment group, visit and treatment group-by-visit 
interaction as categorical fixed effects, baseli ne value and baseline-b y-visit interaction will 
be included as covariates. The least squares means for each dose, the least squares mean 
differences from placebo along with the a ssociated 95% confidence intervals (CIs) and p-
values will be presented. If the normality a ssumption is not met, a nonparametric test will be 
selected for efficacy analysis. Details of norm ality test and nonparametric test will be 
provided in the Statistical Analysis Plan. 
An unstructured covariance matrix will be used to model the within-subject correlation. The 
Kenward-Roger approximation will be used to  adjust the denominator degrees of freedom. 
The analysis will be performed based on al l observed post-baseline scores without any 
imputation of missing data. In the case when  the MMRM fails to converge using an 
unstructured covariance matrix in any stage,  a less stringent covariance matrix (e.g., 
autoregressive 1) will be used. 
Sensitivity analyses will be conducted to ex plore the robustness of the result for primary 
efficacy endpoint based on MMRM. Full de tails will be pre-specified in SAP and 
documented prior to databa se lock of the study. 
The differences in proportions and 95% CIs w ill be based on the normal approximation to 
binomials. 
11.4.4 Efficacy Variables 
The pharmacodynamic efficacy of three Ziltivekimab doses compared to placebo will be 
assessed by [CONTACT_167405]:   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
87 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 88 of 142 [IP_ADDRESS] Primary 
x Difference in percent change in hs-CRP levels from Baseline (average of the hs-CRP 
value prior to randomization and Day 1) to  Week 13 between each active group and 
placebo. 
[IP_ADDRESS] Secondary  
x Difference in change in SAA from Baseline  to Week 13 between each active group and 
placebo. 
x Difference in percent change in fibrinogen from Baseline to Week 13 between each 
active group and placebo. 
[IP_ADDRESS] Exploratory 
x Difference in percent change in hs-CRP levels from Baseline to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in percent change in serum NT-p ro-BNP from Baseline (average of the NT-
pro-BNP value prior to randomization and Day 1) to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change in SAA from Baseline to End of Treatment (Weeks 23 through 
24) between each active group and placebo. 
x Difference in percent change in fibrinogen  from Baseline to End of Treatment (Week 
24) between each active group and placebo. 
x Difference in change in hemoglobin from Ba seline (average of the two most recent 
hemoglobin values prior to randomization and Day 1) to Week 13 and to End of 
Treatment (Weeks 23 through 24) betw een each active group and placebo. 
x Difference in change in serum albumin from Baseline (average of the two most recent 
serum albumin values prior to randomization and Day 1) to Week 13 and to End of Treatment (Weeks 23 through 24) betw een each active group and placebo. 
x Proportion of patients achieving hs-CRP response at Week 13 and to End of Treatment 
(Weeks 23 through 24), defined as hs-CRP < 2.0 mg/L in each active group and placebo. 
x Difference in change in ST2 from Baseline to Week 13 and to End of Treatment (Week 
24) between each active group and placebo. 
x Difference in percent change in Lp(a) from Baseline to Week 13 and to End of 
Treatment (Weeks 23 through 24) betw een each active group and placebo.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
88 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 89 of 142 x Difference in percent change in LDL-C, triglycerides, ApoB, ApoA1, ApoB/ApoA1, 
and lipid profile by [CONTACT_244119] 13 and to End of 
Treatment (Weeks 23 through 24) be tween each active group and placebo. 
x Difference in change of creatinine base d eGFR and cystatin C-based eGFR from 
Baseline to Week 13 and to the End of Tr eatment (Weeks 23 through 24) between each 
active group and placebo. 
x Difference in change of UACR from Baseline  to Week 13 and to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in change of the total fatigue score (PROMIS Fatigue 13a short form and 
selected items from the PROMIS Fatigue item bank) from Baseline to Week 13 and to 
End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change of the PROMIS interest in sexual activity item from Baseline to 
Week 13 and to End of Treatment (Week 24) between each active group and placebo. 
x Difference in change of the Corvidia ePRO items from Baseline to Week 12 and to End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change of the PGIS index from Baseline to Week 12 and to End of Treatment (Week 24) between each active group and placebo. 
x Descriptive analyses of the PGIC index at Weeks 5, 13 and End of Treatment (Week 
24) in each active group and placebo. 
x Difference in change of the Optum SF- 36 v2¬Æ Health Survey physical component 
summary (PCS), mental component summary (MCS) and domain scores from baseline 
to Week 13 and to End of Treatment (Week s 23 through 24) between each active group 
and placebo. 
x Difference in change of the EQ-5D-5L index from Baseline to Week 12 and to End of 
Treatment (Week 24) between each active group and placebo. 
x Evaluation of the psychometric properties of the PROMIS Fatigue 13a short form and 
selected items from the PROMIS Fatigue item bank and the Corvidia ePRO items in 
CKD patients ‚Äì to be described in a PRO psychometric analysis plan. 
x Descriptive analyses by [CONTACT_244120], genomic and transcriptomic analysis. 
x Difference in change in TSAT from Baseline to peak level, Week 13 and End of 
Treatment (Weeks 23 through 24), betwee n each active group and placebo.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
89 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 90 of 142 x Difference in change in CHr from Baseline to peak level, Week 13 and to End of 
Treatment (Week 24) between each active group and placebo. 
x Difference in change in TIBC from Baseline to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change in serum ferritin from Baseline to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo. 
x Difference in change in serum iron from Ba seline to Week 13 and to End of Treatment 
(Weeks 23 through 24) between each active group and placebo. 
x Difference in change in serum hepcidin from Baseline to Week 13 and to End of Treatment (Week 24) between each active group and placebo. 
x Difference in percent change in serum NT-pro-BNP from Baseline to Week 13 and to End of Treatment (Weeks 23 through 24) between each active group and placebo in 
patients with baseline NT-pro-BNP > 250 pg/mL. 
x Difference in change in hemoglobin from Baseline (average of the two most recent 
hemoglobin values prior to randomization and Day 1) to Week 13 and to End of 
Treatment (Weeks 23 through 24) between each active group and placebo in patients with 
baseline hemoglobin < 11 g/dL. 
x Difference in change in serum albumin from Baseline (average of the two most recent 
serum albumin values prior to randomization and Day 1) to Week 13 and to End of 
Treatment (Weeks 23 through 24) between each active group and placebo in patients with 
baseline albumin < 4.0 g/dL. 
For the above efficacy variables, the observed values, changes from baseline, or percent 
changes from baseline (as applicable) w ill be summarized by [CONTACT_244138].  
The PROMIS Fatigue 13a short form contains 13 items that assess symptoms and impacts of 
fatigue ( Appendix B) .  The total score of the PROMIS Fatigue 13a short form and selected 
items from the PROMIS fatigue item bank will  be calculated as a raw score based on the 
average of the items. The observed value and chan ge from baseline in total fatigue score will 
be summarized by [CONTACT_99432].  
The PROMIS Sexual Function and Satisfacti on (PROMIS SexFS) is a customizable self-
reported set of measures that include 79 items in 11 domains, for the purpose of this protocol 
we are only using 1 item: interest in sexual activity, lubrication, vaginal discomfort, erectile 
function, global satisfaction with sex life, orgasm , anal discomfort, therapeutic aids, sexual 
activities, interfering factors, and screener qu estions. The PROMIS evaluations are to be   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
90 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 91 of 142 done on subjects‚Äô device at the clinic PRIOR to dosing.  The observed value and the change 
from baseline will be summarized by [CONTACT_99432].  
The Optum SF-36 v2¬Æ Health Survey is perhaps the most widely used health-related quality 
of life (HRQoL) survey instrument in the worl d today (Hays 2001). It is comprised of 36 
items that assess eight health concepts: phys ical functioning, role limitations caused by 
[CONTACT_244139], role limitations caus ed by [CONTACT_244140], social functioning, 
emotional well-being, energy/fatigue, pain, and general health perceptions ( Appendix C ). 
Physical and mental health summary scores ar e also derived from the eight Optum SF-36 
scales. The PCS, MCS, and domain scores will only be analyzed descriptively. The observed 
value and change from baseline in total Op tum SF-36 v2¬Æ Health Survey score will be 
summarized by [CONTACT_3148]. The Optum eva luations are to be done on subjects‚Äô device at the 
clinic PRIOR to dosing. 
The CARES Corvidia ePRO is a new PRO instrument under development ( Appendix D ).  It 
consists of [ADDRESS_296875] 24 hours on a numeric rating scale from 0 (no symptom) to 
10 (symptom as bad as I can imagine).    
Data will be collected at home on subject‚Äôs pe rsonal device or one provided by [CONTACT_244141]; the 
questionnaire will be answered daily for 7 days prior to dose (Screening Day -7 to Day -1 
prior to Dose 1 (Visit 1), Dose 2 (Visit 4), Do se 4 (Visit 7), and the last 2 weeks after Dose 6 
(Visit 23-24). For each item, weekly scores  will be derived as the average of the 7 
consecutive daily scores as follows: 
Baseline = average of Day -7 to Day -1 
Visit 4 = average of Day 22 to Day 28 
Visit 7 = average of Day 78 to Day 84 
If more than 4 daily scores out of the 7 days  (>50%) within the weekly period are missing, 
then the score is set to missing. 
A bi-weekly score (the End of Treatment) will also be derived as the average of Day 155 to 
Day 168. If more than 8 daily scores out of th e 14 days (>50%) within the bi-weekly period 
are missing, then the score is set to missing. 
Psychometric analyses will be conducted usin g the trial data to assess the psychometric 
properties of the CARES Corvidia ePRO instrum ent. The structural validity of CARES 
Corvidia ePRO instrument will be evaluated by [CONTACT_244142]. A total 
summary scale or set of scales will be proposed in light of the factor loadings as well as 
clinical and conceptual considerations.  Additiona l details will be described in the PAP. The 
score(s) developed as psychometrically sound will be used to evaluate efficacy.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
91 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296876] PRO assessments. The completion rate will be defined as the total 
number of actual completed diary entries divided by [CONTACT_244143] 
a given time period (total number of days X number of expected patients). 
The observed value and change from baseline on  the developed scores will be summarized 
by [CONTACT_244144]. 
The Patients' Global Impression of Change (PGI C) scale and the Patients' Global Impression 
of Severity (PGIS) scale represent clinically relevant tools to assess perceived impact of 
disease management. The PGIC evaluates overall health status as perceived by [CONTACT_89410] 
a seven-point, single-item scale ranging from 'very much worse' to ‚Äòno changes‚Äô to 'very 
much improved‚Äô.   The PGIS is a 5-point scale (from no symptoms to very severe symptoms) 
and patients are asked to rate their overall severi ty of symptoms in the present (e.g., at each 
visit). The PGIC and PGIS are the most commonly used anchor based method of assessing 
clinically important change and severity in which the external judgment of meaningful 
change is made by [CONTACT_102] ( Appendix E ). The PGIC and PGIS evaluations will be done 
on subjects‚Äô device at the clinic PRIOR to dosing . Descriptive statistics (counts and 
percentages) for each response option at ea ch scheduled visit for both PGIC and PGIS 
(separately) will be provided. A stacked column chart showing the distribution of responses 
at each scheduled visit will also be provided. 
The EurQol-5D-5L (EQ-5D-5L) is a standardize d measure of health status developed by [CONTACT_181273] a simple, ge neric measure of health for clinical and 
economic appraisal ( Appendix F ). Applicable to a wide range of health conditions and 
treatments, it provides a simple descriptive profil e and a single index value for health status 
that can be used in the clinical and economic  evaluation of health care as well as in 
population health surveys. EQ-5D is designed for self-completion by [CONTACT_244145], in cl inics, and in face-to-face interviews. It is 
cognitively undemanding, taking only a few minutes to complete. Instructions to respondents 
are included in the questionnaire. 
The EQ-5D- 5L is to be done on a subject‚Äôs device at the clinic PRIOR to dosing. EQ -5D-5L 
consists of two parts: 
x EQ-5D-5L descriptive system 
x Visual Analog Scale (VAS) with instant re call of ‚Äúhow you feel today‚Äù; scale goes 
from 0-100, where [ADDRESS_296877] one. 
The EQ-5D-5L descriptive system includes the basic domains common to each generic 
health status measure: mobility, self-car e, usual activities, pain/discomfort and   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
92 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 93 of 142 anxiety/depression. The instrument includes on e single question per domain. For each 
question, there are 5 levels of responses, corresponding to increasing levels of impairment 
(no problems, slight problems, moderate problems, severe problems, and extreme problems), 
and coded 1 to 5. 
Only descriptive analyses of the EQ-5D-5L resu lts will be presented. Number and percentage 
of patients with each of five levels (no problems,  slight problems, moderate problems, severe 
problems, and extreme problems) of response in each domain will be presented by [CONTACT_131374]. The observed value and change from baseline on the EQ-5D-5L VAS score will be 
summarized by [CONTACT_244144]. 
Additional exploratory analyses of the PROs coll ected in the study will be described in the 
PROSAP. 
[IP_ADDRESS] Multiple Comparisons Procedure for Pr imary Efficacy and Secondary Endpoints 
The overall familywise error rate (FWER) will be controlled at Œ±  = 0. 05 using the sequential 
testing procedure for the primary efficacy endpoi nt comparing between the three dose levels 
of Ziltivekimab vs. placebo. The high dose (30 mg) will be compared with placebo at the 
beginning. If significant then the middle dose (15  mg) will be compared with placebo. If the 
middle dose is significant, then the low dose (7.5 mg) will be compared with placebo. The procedure stops whenever a nonsignificant test occurs. 
Secondary endpoints are not included in the multiplicity control. 
11.4.5 Safety Analysis 
[IP_ADDRESS] Adverse Events 
The adverse event verbatim descriptions (invest igator terms from the CRF) will be classified 
into medical terminology using the Medical Dictionary for Regulatory Activities (MedDRA).  
Adverse events will be coded to primary Syst em Organ Class (SOC) and preferred term (PT) 
using MedDRA, Version 21.0.   
Treatment emergent adverse events (TEAEs) ar e defined as AEs that initiated or worsened 
on or after the date of first dose of study dru g up to the end of safety-follow-up. For AEs 
occurring on the first dosing day, if the start time cannot be ascertained, the event will be 
counted as treatment-emergent. 
Safety events of special interest ( Section 9.3 ) will be summarized by [CONTACT_244146]. An overview of AEs will be provided including c ounts and percentages of subjects with the 
following:   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
93 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 94 of 142 ‚Ä¢ Any TEAEs (overall and by [CONTACT_764]) 
‚Ä¢ Any study drug related TEAEs (overall and by [CONTACT_764]) ‚Ä¢ Any TEAEs of special interest (overall and by [CONTACT_764]) ‚Ä¢ Any serious AEs (SAEs) ‚Ä¢ Any treatment-emergent serious AEs (TESAEs) ‚Ä¢ Any TEAEs leading to discontinuation of study drug ‚Ä¢ Any TEAEs leading to discontinuation of study ‚Ä¢ Any AEs leading to death 
‚Ä¢ Any severe hematologic AEs (see Section [IP_ADDRESS] ) 
‚Ä¢ Any severe non-hematologic AEs 
The number and percentage of patients reportin g TEAEs and SAEs for each preferred term 
will be tabulated by [CONTACT_57501]-organ class, by [CONTACT_57501]- organ class and severity, and by [CONTACT_57501]- 
organ class and relationship to Study Drug. If more than one event occurred with the same 
preferred term for the same patient, the patient will be counted only once for that preferred 
term using the most severe or related occurren ce for the summary by [CONTACT_926], or relationship 
to study drug, respectively. 
Listings will be presented specifically fo r SAEs and TEAEs leading to discontinuation of 
study drug. [IP_ADDRESS] Laboratory Tests 
Laboratory values (excluding efficacy laboratory parameters) will be summarized by 
[CONTACT_1570], including changes f rom baseline at each visit.  
[IP_ADDRESS] Vital Signs 
Vital signs and change from baseline in vital sign s will be summarized descriptively at each 
visit by [CONTACT_1570].  The number and percen tage of patients with exceeding pre-defined 
absolute and relative threshold values will be summarized according to Table [ADDRESS_296878]-baseline outlier value within the an alysis period; and the denominator will be the 
number of subjects with a baseline and at least [ADDRESS_296879]-baseline assessment within the analysis 
period. 
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
94 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 95 of 142 Table 6 Pre-defined Threshold Value for Vital Signs 
Parameter Criteria 
Systolic Blood Pressure (SBP) >25% mmHg increased or de creased from baseline 
SBP >160 mmHg 
SBP <90 mmHg 
Heart Rate (HR) >100 beats per minute 
HR <50 beats per minute 
Respi[INVESTIGATOR_26452]   >24 breaths per minute 
BMI >10% increased from baseline 
BMI >10% decreased from baseline 
 
[IP_ADDRESS] 12-lead ECG 
ECG interpretation (normal vs. abnormal) will  be summarized using frequency and 
percentage at each visit by [CONTACT_1570].  ECG intervals (PR, QT, HR, and QTcF) will be 
summarized descriptively at each visit.  The number and percentage of patients with 
exceeding pre-defined absolute and relative th reshold values will be summarized ( Table 7 ). 
When calculating the percentages for the criteri on related to a threshold, the numerator will 
be the number of subjects with normal baseline with respect to the specific criterion and at 
least [ADDRESS_296880]-baseline outlier value within the analysis period; and the denominator will be the 
number of subjects with a baseline and at least [ADDRESS_296881]-baseline assessment within the analysis 
period. 
 
Table 7 Pre-defined Threshold Value for ECG  
Parameter Criteria 
PR Interval >200 msec 
QTcF  >450 msec 
QTcF >480 msec 
QTcF  >500 msec 
QTcF  Increase from baseline >30 msec 
QTcF Increase from baseline >60 msec 
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
95 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 96 of 142 [IP_ADDRESS] Physical Examination  
Physical examination clinically significant new or worsening findings will be reported as 
adverse events and will therefore be summ arized as described for adverse events. 
[IP_ADDRESS] Antibodies to Ziltivekimab 
The immunogenic potential of Ziltivekimab will  be assessed by [CONTACT_244147] e anti-drug antibodies (ADA).  Anti-drug 
antibody titers will be summarized descriptiv ely for ADA positive samp les and the impact of 
ADA on PK will be assessed if data allows.   
[IP_ADDRESS] Bleeding Events 
Bleeding events will be classified using the TIMI Bleeding Classification in Table 8 . 
 
 
Table 8 TIMI Bleeding Classification  
Parameter Criteria 
Major  Intracranial hemorrhage or a ‚â•5 g/dl decrease in the hemoglobin concentration or a 
‚â•15% abso lute decrease in the hematocrit 
Minor  Observed blood loss: ‚â•3 g/dl decrease in the hemoglobin concentration or ‚â•10% 
decrease in the hematocrit. No observed blood loss: ‚â•4 g/dl decrease in the hemoglobin 
concentration or ‚â•12% decrease in the hematocrit  
Minimal Any clinically overt sign of hemorrhage (including imaging) that is associated with a 
<3 g/dl decrease in the hemoglobin concen tration or <9% decrease in the hematocrit 
All TIMI definitions take into account blood transfusions, so that hemoglobin and hematocrit values are 
adjusted by 1 g/dl or 3%, respectively, for each unit of blood transfused. Therefore, the true change in 
hemoglobin or hematocrit if there has been an interve ning transfusion between two blood measurements is 
calculated as follows: Œî Hemoglobin = [baseline Hgb ‚àí post -transfusion Hgb] + [numbe r of transfused units]; Œî 
Hematocrit = [baseline Hct ‚àí  post -transfusion Hct] + [number of transfused units √ó 3]. 
TIMI = Thrombolysis In Myocardial Infarction. 
Source: Rao 2006  
 
11.4.6 Pharmacokinetic Analysis and Ph armacokinetic/Pharmacodynamic 
Analysis 
[IP_ADDRESS] Pharmacokinetic Data 
A listing of PK blood sample collection times as  well as derived sampling time deviations 
will be provided.  A patient listing of all serum concentration-time data for each dose group 
will be presented.  Ziltivekimab serum concen trations will be summarized by [CONTACT_244148]-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
96 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 97 of 142 nominal time point, using appropriate descriptive statistics (e.g., n, arithmetic mean, standard 
deviation (SD), coefficient of variation (CV),  minimum, median, maximum, geometric mean, 
and geometric CV (GCV).  
For IL-6, results of PK parameters such as C max, AUC, and T 1/2 will be summarized by [CONTACT_61027]. Individual and mean concentration-time profiles will be presented graphically. The data from this study may be used in combin ation with data from other studies to develop 
a population PK model.  If performed, the plan for and results of such analysis will be 
documented separately. 
Pharmacokinetic analysis will be performed separately. 
[IP_ADDRESS] Pharmacokinetic/Pharmacodynamic Analysis 
Pharmacokinetic-pharmacodynamic (PK-PD) mod el parameters will be derived using plasma 
IL-6 levels to describe target engagement, with clinically meaningful PD variables that may 
include one or more of the following: C-reactive protein, serum amyloid A, transferrin 
saturation, hemoglobin, reticulocyte hemoglobin content, or reticulocyte count.  The specific model parameters to be estimate d will be determined based on review of the observed data.  
The PD endpoints to be included in the PD anal ysis will be determined following review of 
the study data. 
A listing of PD blood sample collection times as  well as derived sampling time deviations 
will be provided.  A patient listing of all PD  results and their corresponding change from 
baseline value for each dose group will be presented.  The observed and change from 
baseline serum results will be summarized using descriptive statistics by [CONTACT_7169]. 
Graphical presentations, as appropriate for PD variables, may include: individual observed 
and percent change from baseli ne serum concentration-time curves for each patient on linear 
scale; arithmetic mean serum concentration- time curves by [CONTACT_244149]. 
11.4.7 Exploratory Analyses of Efficacy an d Safety Endpoints Based on Baseline 
Hemoglobin ( ‚â•11 or <11 g/dL).  
Exploratory analyses may be performed for the primary and secondary efficacy endpoints 
with a stratified analysis  by [CONTACT_244097] ( ‚â•11 or <11 g/dL) and CKD stage (3, 4 or 
5). 
11.5 Interim Analyses 
Interim analyses will not be conducted.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
97 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 98 of 142 12 STUDY COMMITTEES 
12.1 Clinical Events Committee 
An independent external Clinical Events Commit tee (CEC) will not be established based on 
the low current event rates in this ongoing trial. 
12.2 Safety Assessment Committee (SAC) 
A Safety Assessment Committee (SAC) will not  be required because the study will be 
unblinded after 13 weeks for the primary analysis, and all safety data will be reviewed at that 
time by [CONTACT_244150]. At the 13-week analysis, only a small internal group of staff at Corvidia and the 
CRO who are uninvolved with running the study w ill know the results. The sites, Corvidia 
and CRO study teams,  study team, CRAs, Investigators and patients will remain 
blinded to treatment for the duration of the trial. 
   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
98 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296882] be reviewed and approved by [CONTACT_244151].  It is the responsibility of the 
Investigator to assure that the study is c onducted in accordance with current country and 
Local Regulations, International Conference on Harmonisation (ICH), GCP, and the Declaration of Helsinki.  A letter, documenting th e approval that specifically identifies the 
protocol by [CONTACT_244152], must be received by [CONTACT_244153].  Amendments to the protocol will be patient to the 
same requirements as the original protocol. 
After the completion or ter mination of the study, the Investigator will submit a report to the 
IRB or IEC. 
13.[ADDRESS_296883] be provided with oral and written information from the 
investigator (or other study staff who are cond ucting the informed consent interview) to 
allow for an informed decision about participati on in the clinical investigation, facilitating 
the potential subject‚Äôs comprehension of the information, providin g adequate opportunity for 
the potential subject to ask questions and to co nsider whether to participate, obtaining the 
potential subject‚Äôs voluntary agreement to participate and continuing to provide information 
as the clinical investigation progresses or as th e subject or situations requires. The process 
must provide sufficient time for subjects to c onsider the information and providing time and 
opportunity for the subjects to ask questi ons and have those questions answered. The 
investigator (or other study staff who are condu cting the informed consent interview) and the 
subject should exchange information and discuss the contents of the informed consent. This 
process must occur under circumstances that mi nimize the possibility of coercion or undue 
influence. Each patient must be provided with  oral and written information describing the 
nature and duration of the study and must sign a written ICF in a language in which the 
patient is fluent before study specific proc edures are conducted.  The signed and dated ICF 
will be retained with the study records.  Each pati ent will also be given a copy of their signed 
ICF.  
13.[ADDRESS_296884] provide Corvidia Therapeutics with the 
following documents (copi[INVESTIGATOR_244090]): 
1. Curriculum vitae of the Investigator and an y sub-Investigators listed on the 1572 
form;   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
99 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 100 of 142 2. A signed copy of the IRB or IEC approval notice for protocol and informed consent; 
3. A copy of the IRB or IEC approved ICF; 
4. Laboratory certification with a list of normal  values for laboratory tests that will be 
conducted at local laboratories; 
5. Completed financial disclosure form for th e Investigator and any sub Investigators 
listed on the 1572 form. 
 
13.4 Data Reporting and Case Report Forms 
Data for each patient will be entered into the CR F and verified by [CONTACT_737]. It is the 
Investigator‚Äôs responsibility to ensure the accu racy, completeness, legibility, and timeliness 
of the data reported on the patient ‚Äôs CRF .  Source documentation supporting the CRF data 
should indicate the patient ‚Äôs participation in the study a nd should document the dates and 
details of study procedures, AEs, and patient ‚Äôs clinical status.  
The Investigator or designated representative should complete the CRF as soon as possible 
after information is collected, preferably on the sa me day that a study patient is seen for an 
examination, treatment, or any other study p rocedure.  Any outstanding entries must be 
completed immediately after the final examinatio n.  CRF data will be processed in a US 21 
Code of Federal Regulations (CFR) Part 11-compliant system. 
13.5 Retention of Data 
U.S. Federal regulations require that a copy of  records (e.g., laboratory data slips, source 
documents, test article disbursement records), whic h support case records of this study, must 
be retained in the files of the responsible Investigator for a minimum of [ADDRESS_296885] be approved  by [CONTACT_244154] ‚Äî before the changes or deviations are impleme nted.  Corvidia Therapeutics will not 
assume any responsibility or liability for any deviation or change.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
100 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 101 of 142 13.7 Study Monitoring 
The Investigator will allow representatives of  Corvidia Therapeutics to periodically audit 
(at mutually convenient times before, during, and after the study has been completed) all 
CRFs and relevant portions of off ice, clinical, and laboratory records for each patient.  
Appropriate source documents such as a record of the patient ‚Äôs medical history and 
concomitant medications from the patient ‚Äôs physician must be available to confirm eligibility 
for the study.  The monitoring visits provide Corvidia Therapeutics with the opportunity to 
evaluate the progress of the study; verify the accuracy and completeness of CRFs; assure that 
all protocol requirements, applicable regulations, and Investigator's obligations are being 
fulfilled; and resolve any inconsistencies in the study records. 
13.[ADDRESS_296886] 
information for this study.  If results of this study are reported in medical journals or at 
meetings, the patient‚Äôs id entity will remain confidential.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
101 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296887]. 
2009;20(5):811 ‚Äì815. 
Aday AW, Ridker PM. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med. 2019 Feb 28;6:16. doi: 10.3389/fcvm.2019.[ZIP_CODE]. eCollection 2019. 
Annuk M, Soveri I, Zilmer M, Lind L. Endothelial function, C-reactive protein and oxidative 
stress in chronic kidney disease. Journal of Nephrology. 1992;18(2):721 ‚Äì726.  
Arici M, Walls J. End stage renal disease, athe rosclerosis, and cardiovascular mortality: Is C-
reactive protein the missing link? Kidney Int. 2001;59:407 ‚Äì417. 
Babitt JL, Lin HY. Mechanisms of Anemia in CKD. J Am Soc Nephrol. 2012 Sep 28; 23(10): 1631 ‚Äì1634. 
B√°r√°ny P, Divino Filho JC, Bergstr√∂m J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997 Apr;29(4):565-8. 
Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, 
Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox). Plasma 
interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis 
patients with chronic kidney disease. Kidney Int. 2010 Mar;77(6):550-6. 
Bayliss TJ1, Smith JT, Schuster M, Dragnev KH, Rigas JR.  A humanized anti-IL-6 antibody 
(ALD518) in non-small cell lung cancer. Expe rt Opin Biol Ther. 2011 Dec;11(12):1663-8. 
Benner D, Brunelli SM, Brosch B, Wheeler J, Nissenson AR. Effects of Oral Nutritional Supplements on Mortality, Missed Dialysis Treatments, and Nutritional Markers in Hemodialysis Patients. J Ren Nutr. 2018 May;28(3):191-196. 
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, 
Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.  N Engl J Med 1998; 
339(9):584-9. 
Biggar P, Kim GH. Treatment of renal anemia: Erythropoiesis stimulating agents and 
beyond. Kidney Res Clin Pract. 2017 Sep;36(3):209-223. 
Bossola M, Di Stasio E, Giungi S, Rosa F, Tazza L. Fatigue is associated with serum 
interleukin-6 levels and symptoms of depression in patients on chronic hemodialysis. J Pain Symptom Manage. 2015 Mar;49(3):578-85.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
102 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296888] and power considerations for multiple endpoint 
analyses using sequentially rejective graphical procedures. Stat Med. 2011 Jun 15;30(13):1489-501. 
Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC: Acute-phase 
response of human hepatocytes: regulation of acut e-phase protein synthesis by [CONTACT_13204]-6. 
Hepatology 1990; 12:1179 ‚Äì1186. 
Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, Wen WF, Wan CH, Wu XM, Chang YY, Wu VC, Wu KD, Lin YH; TAIPAI Study Group. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res. 2018 Apr 1;114(5):690-702.  
Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study 
Group. Ferric gluconate is highly efficacious in  anemic hemodialysis patients with high 
serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18(3):975-84. 
DeFilippi [CONTACT_240316], Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic 
peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis. 2005 Jul;46(1):35-44. 
De Franciso ALM, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in 
CKD; from haemoglobin variability to hy poresponsiveness. Nephrol Dial Transpl Plus. 
2009;2(1):8 ‚Äì26. 
de Mutsert R, Grootendorst DC, Indemans F, Boeschoten EW, Krediet RT, Dekker FW; Netherlands Cooperative Study on the Adequacy of Dialysis-II Study Group. Association between serum albumin and mortality in dial ysis patients is partly explained by 
[CONTACT_2898], and not by [CONTACT_244155]. J Ren Nutr. 2009 Mar;19(2):127-35. 
Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2:1274 ‚Äì82. 
Foley RN, Parfey PS, Sarnak MJ. Clinical epi[INVESTIGATOR_244091]. Am J Kidney Dis. 1998;339:841 ‚Äì843. 
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks 
of death, cardiovascular events, and hospi[INVESTIGATOR_059].  N Engl J Med. 2004 Sep 
23;351(13):1296-305. 
Gregg LP, Hedayati SS. Management of Tradit ional Cardiovascular Risk Factors in CKD: 
What Are the Data? Am J Kidney Dis. 2018 Nov;72(5):728-744. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 
2001 Jul;33(5):350-7.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
103 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 104 of 142 Hentze MW, Muckenthaler M, Galy B, Camaschella C Two to Tango: Regulation of 
Mammalian Iron Metabolism, Cell 2010; 142:24 ‚Äì38. 
Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism., Cell 2004; 117:285 ‚Äì97. 
Herzog CA, Shroff GR. Atherosclerotic versus nonatherosclerotic evaluation: the Yin and 
Yang of cardiovascular imaging in advanced  chronic kidney disease. JACC Cardiovasc 
Imaging. 2014 Jul;7(7):729-32. 
Hung AH, Ellis CD, Shintani A, Booker C, Ikizler A. IL-1B receptor antagonist reduces 
inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22:437-442. 
Jagadeswaran D, Indhumathi E, Hemamalini AJ, Sivakumar V, Soundararajan P, Jayakumar 
M. Inflammation and nutritional status assessm ent by [CONTACT_244156]-dialysis chronic kidney disease patients. Clin Nutr. 2018 Jan 9. pii: S0261-5614(18)[ZIP_CODE]-3. doi: 10.1016/j.clnu.2018.01.001. [Epub ahead of print] 
Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of 
malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance 
hemodialysis patients. Am J Kidney Dis 2003; 42:761 ‚Äì773. 
Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent 
associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16(10):3070 ‚Äì80. 
Kalantar-Zadeh K, Kilpatrick RD, Kuwae N,  McAllister CJ, Alcorn H Jr, Kopple JD, 
Greenland S. Revisiting mortality predictability of serum albumin in the dialysis population: 
time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005 Sep;20(9):1880-8. 
KDIGO Clinical Practice Guideline for Anemia  in Chronic Kidney Disease. Volume 2 (issue 
4); August 2012.  http://www.kidney-international.org; 
http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf 
Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is 
associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 
3(4):1077 ‚Äì83. 
Locatelli F, Marcelli D, Conte F, Del Vecchio, Limido A, Malberti F, et al. Patients selection affects end stage renal disease outcome comparison. Kidney Int. 2000;57(suppl 74):94 ‚Äì99. 
Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, et al. Cardiovascular disease in chroni c renal failure: the challe nge continues. Nephrol Dial 
Transplant. 2000;15(Suppl 5):69 ‚Äì80.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
104 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 105 of 142 Locatelli F, B√°r√°ny P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, H√∂rl W, 
London G, Vanholder R, Van Biesen W; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice pos ition statement. Nephrol Dial Transplant. 2013 
Jun;28(6):1346-59.  
Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y, Du J. Macrophage-stimulated cardiac 
fibroblast production of IL- 6 is essential for TGF Œ≤/Smad activation and cardiac fibrosis 
induced by [CONTACT_244157]. PLoS One. 2012;7(5):e35144.  
Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic 
inflammation. Eur J Clin Invest 2005; [ADDRESS_296889] 3:32-5. 
Mel√©ndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates 
myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010 Aug;56(2):225-31. 
Mercadal L, Metzger M, Casadevall N, Ha ymann JP, Karras A, Boffa JJ, Flamant M, 
Vrtovsnik F, Stengel B, Froissart M; Ne phroTest Study Group. Timing and determinants of 
erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol. 2012 
Jan;7(1):35-42. 
Miyamoto T, Carrero JJ, Qureshi AR, Anderstam B, Heimb√ºrger O, B√°r√°ny P, Lindholm B, 
Stenvinkel P. Circulating follistatin in patients with chronic kidney disease: implications for 
muscle strength, bone mineral density, infl ammation, and survival. Clin J Am Soc Nephrol. 
2011 May;6(5):1001-8. 
Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: an innovative 
therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007 Nov;30(11):2001-6. 
Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY, Choi EJ, Chang YS, Bang BK. 
Increased C-reactive protein following hemodial ysis predicts cardiac hypertrophy in chronic 
hemodialysis patients. Am J Kidney Dis. 2002 Dec;40(6):1230-9. 
Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation and 
atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transpl. 
2002;17(11):28 ‚Äì31. 
Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS. 
Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005 Feb;45(2):324-33.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
105 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 106 of 142 Rao SV, O'Grady K, Pi[INVESTIGATOR_244092], Granger CB, Newby [CONTACT_170284], Mahaffey KW, Moliterno DJ, 
Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Harrington RA. A comparison of the clinical impact of bleeding measured by [CONTACT_244158]. J Am Coll Cardiol. 2006 Feb 21;47(4):809-16. Epub 2006 Jan 26  
Reichert CO, da Cunha J, Levy D, Maselli LMF, By[CONTACT_70976], Spada C. Hepcidin: 
Homeostasis and Diseases Related to Iron Metabolism. Acta Haematol. 2017;137(4):220-
236. 
Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T; CANTOS Pi[INVESTIGATOR_244093]. Effects of interleukin-1Œ≤ inhibition with canakinumab on hemoglobin A1c, lipi[INVESTIGATOR_805], C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, 
placebo-controlled trial. Circulation. 2012 Dec 4;126(23):2739-48.  
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial 
Group. Relationship of C-reactive protein reduc tion to cardiovascular event reduction 
following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 Jan 27;391([ZIP_CODE]):319-328. (Ridker 2018a) 
Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, 
Thuren T, Cornel JH. Inhibition of Interleukin- 1Œ≤ by [CONTACT_244159]. J Am Coll Cardiol. 2018 May 29;71(21):2405-2414. doi: 10.1016/j.jacc.2018.03.490. (Ridker 2018b) 
Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, 
Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-[ADDRESS_296890] 
and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. [ADDRESS_296891] 7;39(38):3499-3507. doi: 10.1093/eurheartj/ehy310. (Ridker 2018c) 
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, 
Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova 
R, Lorenzatti A, Forster T, Kobalava Z, Vida -Simiti L, Flather M, Shimokawa H, Ogawa H, 
Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. 
Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To 
Identify Novel Targets for Atheroprotection. Circ Res. 2016 Jan 8;118(1):145-56. 
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll 
Cardiol. 2008 Nov 4;52(19):1527-39. 
Sakai R, Cho S-KK, Nanki T, Watanabe K, Yama zaki H, Tanaka M, et al.: Head-to-head 
comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid 
arthritis patients (RA) in clinical practice: resu lts from the registry of Japanese RA patients 
on biologics for long-term safety (REAL) registry. Arthritis Res Ther 2015 Jan 4;17:74.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
106 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 107 of 142 [COMPANY_011], Regeneron: Topline Results of Phase 3 Monotherapy Study Demonstrating 
Superiority of Sarilumab vs. Adalimumab in Pa tients with Active Rheumatoid Arthritis 2016 
Mar 11 
Shridas P, Tannock LR. Role of serum amyloid A in atherosclerosis. Curr Opin Lipi[INVESTIGATOR_37487]. 2019 
Aug;30(4):320-325. Sieper J,  Braun J,  Kay J, Badalamenti S, Radin A,  Jiao L,  Fiore S,  et al.  Sarilumab for the 
treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 2015; 74:1051 ‚Äì1057. 
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR 
Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J 
Med. 2006 Nov 16;355(20):2085-98. 
Solbu MD, Mj√∏en G, Mark PB, Holdaas H, Fellstr√∂m B, Schmieder RE, Zannad F, 
Herrington WG, Jardine AG. Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study.Nephrol Dial Transplant. 2018 Jan 1;33(1):102-112. 
Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, Isobe T, Ito H, Kawabata 
H, Yoshizaki K. Comparative evaluation of the effects of treatment with tocilizumab and 
TNF-Œ± inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid 
arthritis patients.  Arthritis Res Ther. [ADDRESS_296892] 2;15(5):R141. 
Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K.  Down-
regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 
2010 Nov 4;116(18):3627-34. 
Spoto B, Mattace-Raso F, Sijbrands E, Leonardis D, Testa A, Pi[INVESTIGATOR_1336] A, Pi[INVESTIGATOR_39063] P, Cutrupi S, 
Parlongo RM, D'Arrigo G, Tripepi G, Mallamaci F, Zoccali C. Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD.  Clin J Am Soc Nephrol. 2015 Feb 6;10(2):232-40. 
Stenvinkel P, Heimb√ºrger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. 
Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999 May;55(5):1899-911. 
Storey BC, Staplin N, Haynes R, Reith C, Emberson J, Herrington WG, Wheeler DC, Walker 
R, Fellstr√∂m B, Wanner C, Landray MJ, Baigent C; SHARP Collaborative Group. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. 
Kidney Int. 2018 Apr;93(4):1000-1007.  
Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new 
treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012; 87(4):392-400.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
107 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 108 of 142 Tanaka Y, Martin Mola E: IL-6 targeting compared to TNF targeting in rheumatoid arthritis: 
studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis 2014 Sep 1;73:1595 ‚Äì7. 
Untersteller K, Girerd N, Duarte K, Rogacev KS, Seiler-Mussler S, Fliser D, Rossignol P, 
Heine GH.  NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular 
Outcomes in Patients with CKD Stages G2-G4. Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1978-1988. 
US Renal Data System, author. 2002 Annual Data Report. Bethesda, MD: The National 
Institutes of Health, National Institute of Diab etes and Digestive and Kidney Diseases; 2002.  
Won HS, Kim HG, Yun YS, Jeon EK, Ko YH, Kim YS, Kim YO, Yoon SA. IL-6 is an 
independent risk factor for resistance to eryt hropoiesis-stimulating agents in hemodialysis 
patients without iron deficiency. Hemodial Int. 2012 Jan;16(1):31-7. 
Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. 
Blood. 2006 Nov 1;108(9):3204-9.    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
108 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296893] a 
narrow therapeutic window.  The use of these medications from one day prior to Randomization (Day -1) through Study Week 24 is prohibited. 
digoxin 
theophylline terfenadine 
tizanidine 
quinidine phenytoin and its derivatives taxane chemotherapeutic agents cyclosporine mTOR inhibitors (e.g., sirolimus, tacrolimus) ergot alkaloids antipsychotic medications (specifically pi[INVESTIGATOR_3924], thioridazine) fentanyl and derivatives (e.g., alfentanil and sufentanil) 
 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
109 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 110 of 142 15.2 Appendix B PROMIS¬Æ (Patient-Reported Outcomes Measurement 
Information System) 
 
     Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
110 of 142

FATEXP36: How exhausted were you on average?
FATEXP43: How physically drained were you on average?
FATIMP52: To what degree did your fatigue make you feel 
less alert?During the past 7 days‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..
I feel fatiguedI feel weak all overI feel listless (‚Äúwashed out‚Äù)I feel tired
I have trouble starting
things because I am tired
I have trouble finishing things because I am tired
I have energy
I am able to do my usual activitiesI need to sleep during the dayI am too tired to eatI need help doing my usual activitiesI am frustrated by [CONTACT_244160] I want to doI have to limit my social activity because I am tired1 2 3 4 5 Not at all A little bit Somewhat Quite a bit Very much
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 PROMIS Items
PROMIS 
Short Form 
v1.0 ‚Äì
Fatigue 
13a
PROMIS 
items 
(Item 
identifier 
in bold)During the past 30 days‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..SFINT101: How interested have you been in sexual activity?
1 2 3 4 5 Not at all A little bit Somewhat Quite a bit Very much  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
111 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 112 of 142 15.3 Appendix C Optum SF- 36 v2¬Æ Health Survey  
 
 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
112 of 142

SF-36v2¬Æ Health Survey ¬î 1992, 2000, [ADDRESS_296894] and QualityMetric Incorporated. All rights reserved. 
SF-36¬Æ is a registered trademark of Medical Outcomes Trust. 
(SF-36v2¬Æ Health Survey Standard, [LOCATION_002] (English))SF-36v2¬Æ Health Survey Single-Item Standard Recall for Handheld Device 
Item Name [CONTACT_244164] 1 Answer 
Text 2Answer 
Text 3Answer 
Text 4Answer 
Text 5Answer 
Text 6 
 Your Health and Well-Being 
This survey asks for your views about 
your health.  This information will help 
keep track of how you feel and how well you are able to do your usual 
activities. Thank you for completing 
this survey! 
For each of the following questions, 
please select the one response that best describes your answer.       
SF36v2_GH1 In general, would you say your health is: Excellent Very good Good Fair Poor  
SF36v2_HT Compared to one year ago, how 
would you rate your health in general now? Much
better
now than 
one year 
agoSomewhat 
better now 
than one 
year ago About the 
same as 
one year 
agoSomewhat 
worse 
now than 
one year 
agoMuch
worse 
now than 
one year 
ago
The following questions are about activities you might do during a typi[INVESTIGATOR_244094].  Does your health now limit you in 
these activities?  If so, how much?       
SF36v2_PF01 Does your health now limit you in 
vigorous activities, such as running, 
lifting heavy objects, participating in 
strenuous sports?  If so, how much? Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF02Does your health now limit you in 
moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, or playing golf?  If so, how much?Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF03Does your health now limit you in 
lifting or carrying groceries?  If so, how 
much?Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF04Does your health now limit you in 
climbing several flights of stairs?  If so, 
how much? Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF05Does your health now limit you in 
climbing one flight of stairs?  If so, 
how much? Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF06Does your health now limit you in 
bending, kneeling, or stoopi[INVESTIGATOR_007]?  If so, how much? Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF07Does your health now limit you in 
walking more than a mile?  If so, how 
much?Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF08Does your health now limit you in 
walking several hundred yards?  If so, 
how much? Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF09Does your health now limit you in 
walking one hundred yards?  If so, 
how much? Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
SF36v2_PF10Does your health now limit you in 
bathing or dressing yourself?  If so, how much? Yes, 
limited a 
lotYes, 
limited a 
little No, not 
limited at 
all     
During the past [ADDRESS_296895] you had any of the 
following problems with your work or other regular daily activities as a result 
of your physical health?         Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
113 of 142

SF-36v2¬Æ Health Survey ¬î 1992, 2000, [ADDRESS_296896] and QualityMetric Incorporated. All rights reserved. 
SF-36¬Æ is a registered trademark of Medical Outcomes Trust. 
(SF-36v2¬Æ Health Survey Standard, [LOCATION_002] (English))Item Name [CONTACT_244164] [ADDRESS_296897] you cut down on the 
amount of time you spent on work or 
other activities as a result of your 
physical health? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_RP2During the past [ADDRESS_296898] you accomplished less 
than you would like as a result of your 
physical health? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_RP3During the past 4 weeks, how much of 
the time were you limited in the kind of 
work or other activities as a result of 
your physical health? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_RP4During the past [ADDRESS_296899] you had difficulty 
performing the work or other activities as a result of your physical health (for 
example, it took extra effort)? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
During the past [ADDRESS_296900] you had any of the following problems with your work or 
other regular daily activities as a result 
of any emotional problems (such as 
feeling depressed or anxious)?       
SF36v2_RE1During the past [ADDRESS_296901] you cut down on the 
amount of time you spent on work or 
other activities as a result of any 
emotional problems (such as feeling 
depressed or anxious)? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_RE2During the past [ADDRESS_296902] you accomplished less 
than you would like as a result of any 
emotional problems (such as feeling 
depressed or anxious)? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_RE3During the past [ADDRESS_296903] you done work or other 
activities less carefully than usual as a 
result of any emotional problems 
(such as feeling depressed or anxious)? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_SF1 During the past 4 weeks, to what 
extent has your physical health or 
emotional problems interfered with 
your normal social activities with 
family, friends, neighbors, or groups? Not at all Slightly Moderately Quite a bit Extremely  
SF36v2_BP1 How much bodily pain have you had 
during the past 4 weeks? None Very mild Mild Moderate Severe Very 
severe 
SF36v2_BP2 During the past 4 weeks, how much 
did pain interfere with your normal 
work (including both work outside the home and housework)? Not at all A little bit Moderately Quite a bit Extremely  
These questions are about how you 
feel and how things have been with 
you during the past [ADDRESS_296904] been feeling.         Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
114 of 142

SF-36v2¬Æ Health Survey ¬î 1992, 2000, [ADDRESS_296905] and QualityMetric Incorporated. All rights reserved. 
SF-36¬Æ is a registered trademark of Medical Outcomes Trust. 
(SF-36v2¬Æ Health Survey Standard, [LOCATION_002] (English))Item Name [CONTACT_244164] [ADDRESS_296906] 
4 weeks did you feel full of life? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_MH1How much of the time during the past 
[ADDRESS_296907] you been very nervous?  All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_MH2How much of the time during the past 
[ADDRESS_296908] you felt so down in the 
dumps that nothing could cheer you 
up?   All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_MH3How much of the time during the past 
[ADDRESS_296909] you felt calm and 
peaceful?All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_VT2How much of the time during the past 
[ADDRESS_296910] a lot of energy?  All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_MH4How much of the time during the past 
[ADDRESS_296911] you felt downhearted 
and depressed?   All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_VT3How much of the time during the past 
4 weeks did you feel worn out?   All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_MH5How much of the time during the past 
[ADDRESS_296912] you been happy?  All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_VT4 How much of the time during the past 
4 weeks did you feel tired?  All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
SF36v2_SF2 During the past 4 weeks, how much of 
the time has your physical health or 
emotional problems interfered with 
your social activities (like visiting with friends, relatives, etc.)? All of the 
timeMost of 
the time Some of 
the time A little of 
the time None of 
the time 
How TRUE or FALSE is each of the 
following statements for you?       
 SF36v2_GH2 I seem to get sick a little easier than 
other people. Definitely 
true Mostly 
true Don't know Mostly 
falseDefinitely 
false
SF36v2_GH3 I am as healthy as anybody I know. Definitely 
true Mostly 
true Don't know Mostly 
falseDefinitely 
false
SF36v2_GH4 I expect my health to get worse. Definitely 
true Mostly 
true Don't know Mostly 
falseDefinitely 
false
SF36v2_GH5 My health is excellent. Definitely 
true Mostly 
true Don't know Mostly 
falseDefinitely 
false
SF-36v2¬Æ Health Survey ¬î 1992,
2000, [ADDRESS_296913] 
and QualityMetric Incorporated. All rights reserved. 
SF-36
¬Æ is a registered trademark of 
Medical Outcomes Trust. 
(SF-36v2¬Æ Health Survey Standard, 
[LOCATION_002] (English))         Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
115 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 116 of 142 15.4 Appendix D Corvidia ePRO 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
116 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
  
Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
117 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
118 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
119 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
120 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
121 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
122 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
123 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
124 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
125 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
126 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
127 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
128 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
129 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
130 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
131 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
132 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
133 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
134 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
135 of 142

Corvidia COR-001-02 ePRO Screenshots 
 
25-Feb-2019 
 Symptom Inventory 
 
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
136 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 137 of 142 15.5 Appendix E PGIS and PGIC 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
137 of 142

  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
138 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page 139 of 142 15.6 Appendix F EurQol-5D-5L (EQ-5D-5L) 
    Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
139 of 142

EQ-5D-5L PDA version
English ([LOCATION_003]) Country (Language)
Health Questionnaire Health Questionnaire
English version for the [LOCATION_003] Version (Target Language)
Version (English)
On the following screens please tap the statem ent that best describes your health TODAY. Instruction
Your mobility TODAY Mobility
I have no problems walking MB1
I have slight problems walking MB2
I have moderate problems walking MB3
I have severe problems walking MB4
I am unable to walk MB5
Your self-care TODAY Self-care
I have no problems washing or dressing myself SC1
I have slight problems washing or dressing myself SC2
I have moderate problems washing or dressing myself SC3
I have severe problems washing or dressing myself SC4
I am unable to wash or dress myself SC5
Your usual activities TODAY  (e.g. work, study, housework, fa mily or leisure activities) Usual Activities
I have no problems doing my usual activities UA1
I have slight problems doing  my usual activities UA2
I have moderate problems doi ng my usual activities UA3
I have severe problems doi ng my usual activities UA4
I am unable to do my usual activities UA5
Your pain / discomfort TODAY Pain / Discomfort
I have no pain or discomfort PD1
I have slight pain or discomfort PD2
I have moderate pain or discomfort PD3
I have severe pain or discomfort PD4
I have extreme pain or discomfort PD5
Your anxiety / depression TODAY Anxiety / Depression
I am not anxious or depressed AD1
I am slightly anxious or depressed AD2
I am moderately anxious or depressed AD3
I am severely anxious or depressed AD4
I am extremely anxious or depressed AD5
We would like to know how good or bad your health is TODAY. Vas Line [ADDRESS_296914] health you can imagine Bottom Scale
YOUR HEALTH TODAY Box Health
¬© EuroQol Research Foundation. EQ-5D‚Ñ¢ is a trade mark of the EuroQol Research Foundation
Disclaimer:  This is a preview of the EQ-5D in strument. It demonstrates the text, ques tions and response options included in 
this version. This preview does not represent the final product and should not be used as an official EQ-5D instrument.
  Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
140 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296915] agree to comply with the contraception and reproduction restrictions of the 
study: 
a) Women of childbearing potential must be using a method of contraception, that is 
‚Äúhighly effective‚Äù (i.e., <1% failure rate)  
OR 
b) Postmenopausal women must have had no menstrual bleeding for at least [ADDRESS_296916] an elevated plasma follicle-stimulating hormone (FSH) level (i.e., >40 mIU/mL) at Screening;  
AND 
b) Postmenopausal ‚Ä¢ All female patients of childbearing potential must have a 
documented negative pregnancy test result at Screening. Pa tients with elevated Œ≤-HCG 
levels believed to be due to end-stage renal disease may be enrolled if documented to not be 
pregnant. 
For the purposes of the proposed study,  ‚Äúhighly effective‚Äù contraceptive methods  are 
defined as those, alone or in combination, that result in a low failure rate (i.e., less than 
1 percent per year) when used consistently and correctly, and include the following: 
x Surgical sterilization at least 6 months  before Study Drug administration 
x Implants 
x LNG and Copper T IUDs 
x Sexual abstinence 
 
Patients who prefer methods which evidence a higher (6-9%) failure rate with typi[INVESTIGATOR_244095].  These methods include the following: 
x Injectable hormone depots 
x Oral contraceptive pi[INVESTIGATOR_4382] 
x Hormone patch 
x Vaginal ring 
 
Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post-ovulation methods) and 
withdrawal are NOT acceptable methods of contraception.   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
141 of 142

A Phase 2 Trial to Evaluate REduction in Inflammation in PatientS with advanced Protocol COR-001-02 
Chronic Renal Disease Utilizing Antibody MEdiated IL-6 inhibition  (RESCUE) 23 December 2019 
  Amendment No. 5 
Corvidia Therapeutics Inc.   
Page [ADDRESS_296917] be willing to use a condom with a partner (male patients with partners of childbearing 
potential must be willing to use 2 effective methods of birth control, 1 should be condom with spermicide) to prevent pregnancy and dr ug exposure of a partner, and refrain from 
donating sperm or fathering a child.  
https://www.cdc.gov/reproductive health/contraception/index.htm 
Investigators may contact [CONTACT_244161].  The guidance will follow that described in the document 
and 
will comply with FDA M3(R2).   Protocol Amendment  COR-001-02_ProtAmend_V5_23Dec2019 | 
EX6018 -4779
142 of 142
